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ABSTRACT
Overexpression of HOXB4, a member of Homeobox transcription factor family,
promotes expansion of hematopoietic stem and progenitor cells both in vivo and
in vitro. However, the molecular mechanisms underlying this effect are not well
understood. In order to identify direct target genes of HOXB4 in primary murine
hematopoietice progenitor cells, we induced HOXB4 function in lineage-negative,
murine bone marrow cells, using a tamoxifen-inducible HOXB4-ERT2 fusion
protein. Seventy seven genes with differentially changed expression in early
response to HOXB4 have been identified as candidate target genes. Among
them, we show that Hemogen (Hemgn), encoding a nuclear protein specifically
expressed in hematopoietic stem and progenitor cells, is a direct transcriptional
target of HOXB4, and that HOXB4 binds to the promoter region of Hemgn. More
importantly, when overexpressed in bone marrow cells, Hemgn promotes
expansion of 5-fluorouracil (5-FU) treated bone marrow cells in both liquid and
semi-solid cultures, recapitulating the effects of HOXB4. Furthermore, both
Hemgn and HOXB4 can protect bone marrow cells from apoptosis. Our results
identify an important direct transcriptional target of HOXB4 that can confer
expansion of primitive myeloid progenitor cells.
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CHAPTER 1. INTRODUCTION
1.1 Hematopoiesis
Hematopoiesis is a process of successive formation and development of blood
cells derived from hematopoietic stem cells.1 Hematopoietic stem cells can
generate multi-lineage or single-lineage commited hematopoietic progenitor cells
for mature blood cells production. Within multi-lineage hematopoietic progenitor
cells, common lymphoid progenitors (CLPs) can give rise to B and T
lymphocytes; on the other hand, common myeloid progenitors (CMPs) can give
rise to various multi- or single-lineage hematopoietic progenitor cells to produce
platelets, erythrocytes, granucytes and monocytes (Figure 1-1).2-6 In humans,
hematopoiesis originates in blood islands in the embryonic yolk sac; then
switches to fetal liver, and then to spleen as adult hematopoietic stem cells
migrate to these locations. In adults, bone marrow is the major site of
hematopoiesis.
Hematopoietic cells are short-lived, thus, to maintain cellular homeostasis,
continuous generation of hematopoietic cells is required. This process is
regulated by a complex balance between cell self-renewal, differentiation and
apoptosis.7-10
1.2 Hematopoietic Stem and Progenitor Cells
Hematopoietic stem cells were originally identified by Till and McCulloch in
mouse transplantation assays.11 Hematopoietic stem cells are self-renewing cells
that have the ability to differentiate into all of the blood cell lineages.12;13
There are two kinds of hematopoietic stem cells that can be isolated in mice ─
embryonic hematopoietic stem cells and adult hematopoietic stem cells.14;15
Embryonic hematopoietic stem cells develop in the yolk sac at day 9.0 of
embryogenesis (E9.0) and can reconstitute hematopoiesis after injection into
neonatal mice. Adult hematopoietic stem cells emerge in the aorta, gonads, and
mesonephros (AGM) region around E10.0 and can reconstitute hematopoiesis in
lethally-irradiated adult mice. The most stringent method to evaluate and quantify
hematopoietic stem cells is to transplant them into lethally-irradiated recipient
animals. In vivo studies show that one single hematopoietic stem cell is sufficient
to restore the whole blood system in lethally irradiated recipient mice.16
Hematopoietic stem cells can be isolated from bone marrow by various methods.
One approach is to use antibodies that enrich for cells expressing hematopoietic
stem cell-associated cell surface markers (e.g., c-kit, Sca-1, Thy1.1) and are
depleted of cells expressing mature lineage markers (e.g., Ter119, B220, CD3,
Mac-1, Gr-1). Hematopoietic stem cell activity resides in a very small proportion
of bone marrow cells, characterized by the Lin-CD41-CD48-CD150+ or
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Figure 1-1. Hematopoiesis.
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Lin-Sca1+CD117+ (LSK) phenotype.17 After injection into lethally-irradiated
recipient mice, these cells migrate to appropriate microenvironmental niches and
undergo rapid expansion and differentiation. In the short term, they provide
radioprotection by generating mature erythroid and myeloid cells that are
necessary for survival. Hematopoietic stem cells also self-renew to generate
more stem cells and sustain steady-state hematopoiesis during the lifetime of an
organism.18;19 Hematopoietic stem cells are less well-defined in humans due to
the lack of an equivalent repopulating assay suitable for quantitate experiments,
although xenograft studies in immunodeficient mice are increasingly used for this
purpose.
Under homeostatic conditions in vivo, most hematopoietic stem cells and some
hematopoietic progenitor cells are in the G0 phase of cell cycle. Many of the late
and more committed hematopoietic progenitor cells are actively proliferating to
generate mature offsprings. Once hematopoietic stem and progenitor cells are
stimulated to enter cell cycle, several outcomes are possible (Figure 1-2).20 First,
they can divide into committed daughter cells in the process of differentiation.
Under stressful conditions in vivo, such as bleeding or infection, this process can
generate mature blood cells to replenish the loss or to increase the immune
response. Under unfavorable in vitro culture conditions, hematopoietic stem and
progenitor cells can also undergo differentiation and lose their original stem and
progenitor cell characteristics. Hematopoietic stem cells can also undergo selfrenewal by dividing into two daughter cells which retain the biological properties
of the original cell. Third, under homeostatic conditions in vivo, apoptosis can
occur and serve to balance the proliferation and differentiation processes.21;22
Committed hematopoietic progenitor cells can enter a transient state of rapid
cell expansion. After exhausting their expansion potential, these cells withdraw
from cell cycle and progressively acquires characteristics of a predetermined
blood cell type.20 The commitment of hematopoietic progenitor cells depends on
specific growth factors and particular microenvironmental signals. Hematopoietic
stem cells reside and develop on stroma cells, such as fat cells, endothelial cells,
fibroblasts, and macrophages. These nonhematopoietic cells provide
microenvironmental signals that support the growth and differentiation of
hematopoietic cells.23-30
1.3 Factors in Hematopoietic Stem and Progenitor Cell Self-Renewal
While the phenotypic and functional properties of hematopoietic stem cells
have been extensively characterized, a fundamental question that remains is
how self-renewal is regulated. One of the most essential issues in stem cell
research is to understand the mechanism of hematopoietic stem and progenitor
cells self-renewal, due to its significance in both basic research and clinical
applications. Identifying the molecules for promoting hematopoietic stem cells
self-renewal may eventually allow the generation of expanded populations of

3

Figure 1-2. Hematopoietic stem cell outcomes.
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hematopoietic stem cells in vitro that can be used therapeutically. Self-renewal
requires the combination of both survival and proliferation pathways, and
inhibition of apoptosis and differentiation signals, which appears to be controlled
both by extrinsic signals from the microenvironment and by intrinsic genetic
programs.31;32 For cell-extrinsic pathways, recent results suggest that the
osteoblastic niche could impact hematopoietic stem cell function. It has been
proposed that hematopoietic stem cells reside in a specific microenvironment,
osteoblastic niche, which is composed of the non-hematopoietic stroma cells,
locally released cytokines, and the extracellular matrix. All these factors act
together to sustain hematopoietic stem cells in bone marrow.24;26-30;33;34 For cellintrinsic genetic programs involved in hematopoietic stem and progenitor cell self
renewal, cell cycle regulators, anti-apoptotic proteins, signal transducers, and
transcription factors have been proven to play essential roles.
1.3.1 Microenvironment
Genetic studies have demonstrated that osteoblasts are a crucial cellular
element of the hematopoietic stem cell niche in bone marrow.35;36 Hematopoietic
stem cells receive critical signals from stroma cells and extracellular matrix
(ECM) for expansion and differentiation. Some components of the ECM can bind
to growth factors produced by stroma cells and also can bind to glycoproteins
expressed on the cell surface of hematopoietic stem and progenitor cells. The
interaction between hematopoietic stem cells and a component of
ECM─fibronectin (FN) can stimulate growth and survival.37 This interaction is
augmented by angiopoietin 1(Ang-1) which is expressed by both osteoblasts and
hematopoietic stem cells. This cytokine acts through the hematopoietic stem cellsurface receptor Tie-2 for maintaining the self-renewal ability.38;39 The direct
interaction between hematopoietic stem cells and stroma cells or ECM in the
niche can also promote hematopoietic stem cell self-renewal. For example,
activation of Notch transmembrane receptors expressed in hematopoietic stem
cells by their corresponding ligands expressed on stroma cells such as Jagged 1
and Jagged 2, can promote the self-renewal process.40-44 Inhibition of Notch
signaling in adult hematopoietic stem cells led to accelerated differentiation in
vitro and depletion of stem cells in vivo.45 Retroviral overexpression of a
dominant active form of Notch established immortalized hematopoietic stem cells
that were dependent on a cytokine cocktail of SCF, IL-6, IL-11 and Flt3 ligand.
Enhanced activation of Notch1 or Notch4 (also known as Int3) contributed to
increased self-renewal ability and consequent differentiation inhibition of
hematopoietic stem cells, providing further evidence of the role of Notch
signaling.46;47 The Wnt pathway, which functions during development for initiating
cellular events such as cell proliferation and differentiation, is also shown to be
involved in this process. For example, it has been shown that Wnt3A and βcatenin play key roles in hematopoietic stem cell self-renewal.48;49

5

1.3.2 Cytokines
Cytokines are a broad family of proteins that mediate positive and negative
signals that control cellular quiescence, apoptosis, proliferation, and
differentiation. In general, cytokines function by engaging a specific receptor and
activating a variety of signaling pathways.50 Among the different cytokines, stem
cell factor (SCF), interleukin-3(IL-3), IL-6, Flt3 ligand, thrombopoietin (TPO) have
been shown to modestly expand hematopoietic stem cells in vitro.51-54 The
combination of SCF, IL-6, TPO and Flt3 ligand can promote transient
hematopoietic stem cell expansion in vitro.55 Particularly, the combination of
SCF, IL-3 and IL-6 was demonstrated to increase the retrovirus-mediated gene
transduction efficiency in murine hematopoietic stem cells.56;57 Some cytokines
such as IL-3 and SCF induce cell proliferation of hematopoietic stem and
progenitor cells, while others such as Flt-3 ligand and kit ligand protect cells from
apoptosis and sensitize them to the effects of growth promoting cytokines.58-60 In
contrast, TGF-β1 can inhibit the growth of hematopoietic stem cells.61;62 The
inhibition of TGF-β1 production by antisense oligos can promote the release of
hematopoietic stem cells from quiescence.63;64 Another TGF- β family member,
bone morphogenetic protein-4 (BMP4) and its upsteam regulator sonic hedgehog
(shh) is able to induce hematopoietic stem cell self-renewal.65;66
1.3.3 Cell Cycle and Apoptotic Regulators
A key mediator of hematopoietic stem cell maintenance is a G1 checkpoint
regulator, the cyclin-dependent kinase inhibitor p21cip1/ waf1 (p21).67;68 In p21−/−
mice, the number of hematopoietic stem cells was increased at steady state
conditions but hematopoietic failure occurred under conditions of stress.
Hematopoietic stem cell self-renewal failure had been observed during the serial
transplantation of p21−/− cells. Another example is a cell cycle inhibitor, p18INK4C.
The absence of p18INK4C led to increased hematopoietic stem cell self-renewal.69
Therefore, intricate control of the cell cycle machinery is required for self-renewal
regulation.
A large body of evidence suggests that suppression of apoptosis is required
for hematopoietic stem cell survival. Studies using transgenic mice constitutively
expressing BCL2 (B-cell lymphoma 2) in all hematopoietic tissues provided
evidence directly supporting this hypothesis. The forced expression of the Bcl2
oncogene resulted in increased numbers of transgenic hematopoietic stem cells
in vivo and those cells showed a competitive advantage over wild type cells in
competitive reconstitution experiments in vivo,10;21;22 suggesting that cell death
plays a role in regulating the homeostasis of hematopoietic stem cells. Recently,
Mcl1 (Myeloid cell leukemia 1), another anti-apoptotic Bcl2 family member, has
also been shown to be required for hematopoietic stem and progenitor cell
survival.70 These results indicate that anti-apoptotic signals may contribute to
regulating hematopoietic stem cell numbers.
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1.3.4 Signal Transducer and Transcriptional Factors
The Pten (phosphatase and tensin homologue deleted on chromosome ten)
tumor suppressor, a modulator of several major signaling pathways, has recently
been implicated as a regulator of hematopoietic stem cell self-renewal and an
initiator of leukemogenesis. Pten functions by inhibiting signaling through the
AKT pathway.71;72 Although Pten deletion initially led to a transient expansion of
hematopoietic stem cell numbers, the hematopoietic stem cell pool in mutant
mice become depleted over time. Pten-deficient hematopoietic stem cells
engrafted normally in recipient mice, but were unable to sustain multilineage
hematopoietic reconstitution over time.71;72
Many transcription factors play important roles in regulating hematopoietic
stem cell self-renewal. c-Myb can promote the growth of hematopoietic stem
cells possibly through the induction of c-myc and the upregulation of c-kit and
Flt3.73;74 c-Myb deficient mice die at embryonic day 15.5 due to a defect in
definitive hematopoiesis.75 PcG (polycomb group) genes are involved in the
maintenance of cellular memory through epigenetic chromatin modifications.
Recent studies have shown that PcG proteins are important in the regulation of
hematopoietic stem cell self-renewal, a process in which cellular memory is
maintained through cell division. Members of the PRC1 (Polycomb repression
complex 1), such as Bmi1(Bone marrow I-1), rae28 and Mel-18, which form
DNA-binding protein complexes with gene-suppressing activity, were shown to
be involved in lympho-hematopoiesis.76 Among these genes, Bmi1 plays an
important role in regulating the proliferative activity of stem and progenitor
cells.77-79 Bmi1 was able to enhance symmetrical expansion of the stem cell pool
through self-renewal, induce a marked in vitro expansion of multipotent
progenitors, and increase the ability of stem cells to repopulate bone marrow in
vivo.80 Rae28-deficient hematopoietic stem cells were defective in long-term
repopulating ability in serial transplantation experiments.81;82 Loss or knockdown
of Mel18 leads to increased expression of Hoxb4, and transplanted Mel18deficient bone marrow showed increased hematopoietic stem cell numbers, but a
decrease in activity due to arrest in the G0 phase of the cell cycle.83 Gfi1 (Growth
factor independence 1), a Zinc-finger repressor of transcription, has been
recently implicated as a regulator of hematopoietic stem cell self-renewal. It was
determined that Gfi1 controls self-renewal by restraining stem cell proliferative
potential.84;85 Gfi1-deficient hematopoietic stem cells displayed increased
proliferation rates and were functionally compromised in competitive repopulation
and serial transplantation assays. Gfi1 might exert these effects by regulating the
cell cycle inhibitor p21CIP1/WAF1, as p21 mRNA expression levels were
dramatically lower in the Gfi1-deficient hematopoietic stem cells.85 p21CIP1/WAF1
itself was also implicated in the regulation of hematopoietic stem cells.68 In its
absence, hematopoietic stem cells had impaired serial transplantation capacity.
Activation of the Stat5 transcription factor in hematopoietic stem cells led to the
dramatic expansion of multipotent progenitors and promoted hematopoietic stem
cell self-renewal in vitro.86 Deletion of Stat5 resulted in profound defects in
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hematopoiesis and markedly reduced ability of the mutant cells to reconstitute in
lethally irradiated mice.87 Transduction of adult mouse bone marrow cells with a
constitutively activated form of Stat3 increased their regenerative activity in
lethally irradiated recipients, whereas the transduction of these cells with a
dominant negative form of Stat3 suppressed their regenerative activity.88 These
studies suggest that Stat proteins play a role in hematopoietic stem cell selfrenewal. The Hox (homeobox) genes encode transcription factors that regulate
embryonic body patterning and organogenesis. They play important roles in the
regulation of hematopoiesis. Overexpression of HOXB4 in bone marrow cells,
which we will discuss in further detail, led to dramatic expansion of hematopoietic
stem cells in vivo and in vitro.89-91
1.4 Expanding Hematopoietic Stem Cells for Transplantation
Understanding the ability of hematopoietic stem cells to replenish themselves
and identifying molecules that promote their expansion in vitro is an important
clinical goal, since several clinical applications for hematopoietic stem cell
expansion could be realized if effective expansion can be achieved.3;91 For
example, the use of cord blood as a source of hematopoietic stem cells for
allogeneic transplantation has been limited by the relatively small number of stem
cells in a single harvest.92 However, due to their low frequency and the difficulties
in culturing stem cells in vitro, effective expansion has not yet been achieved. In
vitro culture systems are insufficient to establish the self-renewing capacity of
hematopoietic stem cells in general, and often result in differentiation and
apoptosis and thus loss of repopulating avtivity.91 Thus, new approaches for the
in vitro expansion of hematopoietic stem cells are needed.91 Although progress
has been made in identifying conditions that maintain hematopoietic stem cell
activity in culture for a brief period of time,93 it has proven difficult to identify
combinations of growth factors that cause significant expansion in culture of
hematopoietic stem cells. In most cases, combinations of growth factors that can
induce proliferation are unable to prevent differentiation of hematopoietic stem
cells in long-term cultures.94
Assorted signaling molecules and transcription factors have been introduced
into hematopoietic stem cells to induce in vitro expansion or immortalization of
cells. However, many attempts were unsuccessful because of the inadequate
expansion or the unintended induction of leukemias. Ectopic expression of the
transcription factor HOXB4 has been shown to dramatically increase the
numbers of transplantable hematopoietic stem cells both in vivo and in vitro, and
may be the most promising approach.90;95
Genetic manipulation of hematopoietic stem and progenitor cells is one
important tool for experimental hematology. Successful generation of
hematopoietic cells from embryonic stem (ES) cells could provide safe and
histocompatible hematopoietic stem cells.96 However, achieving stable long-term
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blood engraftment of ES cell-derived hematopoietic stem cells in irradiated mice
has proven difficult. To improve the hematopoietic activity of induced
hematopoietic cells from ES cells, genetic manipulation was attempted using
transcription factors, such as Lhx-2 and GATA-2, or the oncogenic chimeric gene
bcr-abl. However, these trials produced limited improvement in ES cell-induced
hematopoietic activities. In contrast, enforced HOXB4 expression brought about
the best results by promoting the generation of expanded hematopoietic stem
cells with reconstitution ability.97 Considering the multitude of biological and
ethical challenges facing the use of human ES cells at present, expansion of
hematopoietic stem cells represents a more realistic and feasible goal.98
Four factors (Oct3/4, Sox2, c-Myc, and Klf4) transferred in the mouse oocyte
can reprogram mouse embryonic or adult fibroblast cells into pluripotent stem
cells that exhibit the essential characteristics of embryonic stem cells.99
Subcutaneous transplantation of these induced pluipotent stem (iPS) cells into
nude mice resulted in tumors containing a variety of tissues from all three germ
layers. Following injection into blastocysts, iPS cells contributed to mouse
embryonic development. Generation of hematopoietic stem cells from the iPS
cells should be useful in the applications in transplantation.
1.5 Characteristics of Hox Gene Family Members
Mammalian Hox genes encode homeodomain transcription factors which play
important roles in embryonic body patterning and organogenesis. These genes
were initially identified by homology with fruit fly Drosophila Hom genes.100;101 In
human and mouse, the Hox gene family contains 39 members arranged in 4
distinct clusters (A, B, C, D) on different chromosomes (human 7, 17, 12 and 2;
mouse 6, 11, 15, and 2 respectively) and 13 paralog groups (Figure
1-3).102-104 The 3’ to 5’ chromosomal organization of the genes in each Hox
cluster corresponds to their anterior-posterior axis expression pattern in the body,
that is, 3’ genes affect development of cephalic structures and 5’ genes control
caudal organs.102 Hox genes also show temporal colinearity in expression during
development from anterior to posterior direction. The 3’ genes are expressed
earlier than 5’ genes. In general, members of the same homology group are
expressed at the same time and have the same anterior boundary of
expression.103 This orderly activation of Hox genes is also essential for normal
hematopoietic development.105 The Hox genes we described here belong to the
class I group. There is another group of genes other than Hox genes in the
homeobox gene family, and they are named as nonclustered or divergent
homeobox genes.106;107 The divergent homeobox genes are scattered throughout
the genome and classified into different small groups based on the similarity in
their sequence. In this dissertation, we only focus on the class I, clustered
homeobox genes (Hox genes).
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Figure 1-3. Genomic organization and collinear expression patterns of
Drosophila Hom genes and mammalian Hox genes.
Reprinted with permission from Pediatric Research. Mark M, Rijli FM, Chambon
P. Homeobox genes in embryogenesis and pathogenesis. Pediatr.Res.
1997;42:421-429.
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1.5.1 Functions of Hox Family Members in Hematopoiesis
The Hox family members of transcription factors are functionally involved in
both normal and leukemic hematopoiesis. Genes 3’ in the Hox cluster are
maximally expressed in hematopoietic stem cells; in contrast, genes 5’ in the
cluster from Hox7 to Hox11 are maximally expressed in more committed
hematopoietic progenitor cells.105 Furthermore, expression of Hox7 to Hox11
decreases during differentiation but is maintained in mature blood cells.105
Perturbation of orderly Hox gene expression can result in hematologic
abnormalities.108 Elevated expression of HOX7-11, HOXB6 and HOXB8 has
been reported in human acute myeloid malignancies.109-112 Disregulation of these
Hox proteins in mice also causes hematological abnormalities.113;114 Hox genes
are also involved in chromosomal translocations seen in human leukemias. For
instence, the NUP98 gene at chromosome band 11p15 can undergo
chromosomal translocation and be fused to a number of hox family members
including HOXA9, HOXA11, HOXA13, HOXC11, HOXC13, HOXD9, HOXD11
and HOXD13 in various hematological malignancies such as myelodysplastic
syndromes and acute myeloid leukemia.115-117
The functions of several Hox genes, especially those that are highly expressed
in immature hematopoietic cells (e.g. Hoxa9, a10, b3 and b4), have been studied
extensively. For example, overexpression of Hoxb3 impairs lymphoid
development but enhances myeloid development.118 HOXB4 enhances the in
vivo repopulating activity of hematopoietic stem cells.95 HOXB4 also induces a
40-fold in vitro expansion of mouse hematopoietic stem cells in cultures
containing IL-3, IL-6 and SCF.90 HOXB4 enhances hematopoietic stem cell
proliferation or the probability of self-renewal, although the gene is not
leukemogenic. The genes of trans-paralogs which occupy the same relative
location along the 3’ to 5’ axis along the chromosomes are named with same
number, and they share a relatively high degree of sequence.104 Thus, it is
suggested that paralogous genes can act as redundant factors with similar
functions. For example, Hoxa3 and Hoxd3 provide equivalent function in gene
swapping experiments.119 Another example is Hoxa4, Hoxb4, Hoxc4 and
Hoxd4.120 Overexpression of Hoxc4, a paralog of Hoxb4, also induces in vitro
expansion of human immature hematopoietic progenitors.121 These findings
suggest the importance of the four paralog groups of Hox genes for
hematopoietic stem cell expansion. Although there are no obvious hematological
abnormalities in mice deficient in Hoxb4 alone, hematopoietic stem cells and
progenitor cells deficient in Hoxb3 and Hoxb4 displayed mildly impaired activity
both in vitro and in vivo.122
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1.5.2 Biochemical Characteristics of HOXB4 and Other Hox Family
Members
Mammalian Hox genes usually have relatively small coding sequences with
only two exons and a single intron. All contain a highly conserved 60 amino acid
common homeobox domain (homeodomain) which contains a helix-turn-helix
DNA binding motif encoded by the second exon of Hox genes.111 In HOXB4, the
homeodomain contains 3 α-helices (Figure 1-4A), among which, helix 3 contacts
the major groove of DNA recognizing a conserved “TAAT” core. Helix 1 and 2 do
not contact the DNA but stabilize the protein-DNA interaction. The flexible Nterminal domain located just adjacent to helix 1 in the homeodomain extends
from the packed helical structure and interacts with the minor groove of DNA to
recognize 5’ and 3’ flanking sequences adjacent to the core consensus
sequence.123;124 There is a c-terminus acidic domain and a conserved YPWM
region upstream of homeodomain in Hox proteins. The YPWM region binds to
TALE (three amino acid loop extension) transcription factor family members
which act as cofactors of Hox to increase DNA binding specificity and activity of
Hox-cofactor complexes.125-128
Functional specificity of Hox proteins depends on a number of factors including
their specific expression pattern, the particular interacting proteins present in a
cell, and the specificity of the particular homeodomain regioin. Due to the high
degree of homology within the homeodomain, a core DNA sequence “TAAT” is
recognized and bound by a majority of Hox proteins,128 raising the question of
how the transcriptional and thus functional specificity of these Hox family
members is realized. Hox proteins can elicit distinct and variable effects on
downstream target genes to regulate variety aspects of developmental fates.
Indeed, the DNA binding specificity, affinity and transregulating potential of a
specific Hox protein can be modified by the flanking DNA sequence or interaction
with cofactors.129-131 Hox family members bind to their specific preferred DNA
sequence as monomers or as heterdimers with other cofactors (Figure 1-4B),
although some deficiencies are thought to exist in monomer binding activity of
Hox proteins to DNA. DNA binding affinity of Hox proteins can also be regulated
by posttranslational modifications. For example, PKC (protein kinase C) dependent serine and threonine phosphorylation can decrease the binding
affinity of Hoxa9 to its specific DNA consensus sequence.132 Phosphorylation of
conserved homeodomain tyrosine residues decreases the DNA binding ability of
Hoxa10 to some DNA sequences, but increases the binding affinity of Hoxa9 to
other DNA sites.133;134 Hox proteins form heterdimers with Pbx or Meis members
of the TALE family of transcription factors (Figure 1-4B).135 Hox homologs 1 to 10
can cooperatively bind to DNA through interaction with Pbx in the core YPWM
residues 5’ upstream of homeodomain of HOXB4. Hox homologs 9 to 13 can
directly interact with Meis.136 Hox homologs 9 and 10 can interact with both Pbx
and Meis, and functional trimeric interactions between them have been
reported.137 Interaction with these TALE family cofactors is hypothesized to
increase the DNA binding ability of some Hox family members to their target
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Figure 1-4. Biochemical characteristics of Hox proteins. (A) Functional
domains of HOXB4. (B) Cofactors and DNA binding specificity of Hox family
members.
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genes.138 In addition, the transcriptional specificity of Hox proteins also lies in
their ability to act both as transcriptional activators and repressors in different
conditions. The complexity of Hox regulation of downstream target genes is
underscored by the observation that they can regulate different target genes
either dependent or independent of TALE family cofactors.133;139
It is known that HOXB4 regulates hematopoietic stem and progenitor cell
expansion through a transcription-dependent mechanism.140 A HOXB4 mutant
incompetent for DNA binding failed to cause the proliferation of transduced bone
marrow in vitro and hematopoietic stem cell expansion in vivo.140 Similar to other
Hox family members, HOXB4 contains a homeodomain that is required for DNA
binding. In this homeodomain, the helix 3 region is essential for recognizing and
interacting with the consensus DNA regulatory element containing “TAAT” or
“ATTA” core sequence in the promoters of Hox target genes. In vitro studies
have proven that HOXB4 has preference for specific flanking nucleotides (Figure
1-5).129 HOXB4 can cooperatively bind to 5’ TGATTAAT 3’ sequences with its
cofactor Pbx through its “YPWN” residues. However, it was demonstrated that a
HOXB4 mutant that cannot bind Pbx was functional and caused in vitro
proliferation and elevated in vivo regenerative potential in bone marrow cells.140
The proline-rich N-terminus region of HOXB4 is conserved in other proteins such
as p53, AP2, HOXD4 and HOXA13, in which it functions as a transactivation
domain.
1.5.3 Hox Downstream Target Genes
Hox transcription factor family members can act as key masters for controlling
cellular identity and play critical roles in controlling embryogenesis and organ
development. Although much is now known about their regulation and function,
very little is known of their effector genes. Recent studies have focused on
identifying their common or unique downstream target genes to facilitate
understanding of their functions, especially in the process of normal and
malignant hematopoiesis. Such understanding may provide means for
hematopoietic stem cell engineering approaches to hematopoietic. For the
purpose of identifying downstream target genes, various approaches have been
taken including high throughput genetic screens, in which, the gene expression
profiles of cells overexpressing specific Hox proteins are analyzed.
A small number of Hox target genes have been identified in different biological
systems that play roles in cellular identity and function. However, the
experimental procedures used for identification of each target gene sometimes
make it difficult to determine whether they are truly direct targets. For instance,
for some direct targets, the DNA sites bound by Hox factors have not been
confirmed experimentally. A summary of identified Hox target genes which are
involved in a variety of cellular processes have been reported.141 In the list
outlined in this review,141 the identified target genes of Hox proteins participate in
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Figure 1-5. HOXB4 has preference for the nucleotides flanking the “TAAT”
core binding sequence.
Source: Pellerin I, Schnabel C, Catron KM, Abate C. Hox proteins have different
affinity for a consensus DNA site that correlate with the positions of their genes
on the hox cluster. Mol.Cell Biol. 1994;14:4532-4545.
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organogenesis and cellular differentiation, cell adhesion and migration, cell cycle
and apoptotic pathways.
The TALE class homeodomain transcription factor Irx5 and the small GTPase
Rap1 were reported to be regulated by Hoxb4 in development.142;143 However, no
specific target genes of HOXB4 have been identified in hematopoietic cells untill
recently. There is only one report that addresses the targets of HOXB4 in
hematopoietic cells.144 In this report, the downstream pathways ectopically
expressed HOXB4 were identified in adult and embryo-derived hematopoietic
stem cells. Gene expression profiling assays were performed in combination with
functional assays using enriched adult hematopoietic stem cells and embryonic
derivatives overexpressing an inducible form of HOXB4. A set of overlapping
genetic changes was generated from these systems and selected to represent
common targets of HOXB4 in embryonic and adult hematopoietic stem cells.144
In functional assays, HOXB4 activity was found to protect adult hematopoietic
stem cells from the detrimental effects of the proinflammatory cytokine TNF-α,
which likely contributes to the competitive repopulation advantage of HOXB4overexpressing cells in vivo.144 It was also demonstrated that HOXB4 activity and
FGF signaling were intertwined, since HOXB4-mediated expansion of adult and
ES cell-derived hematopoietic stem cells was enhanced by inhibition of FGF
receptors.144 In this report, however, no evidence was provided to prove that any
of the target genes was a direct transcriptional target of HOXB4. Instead, their
data suggest that multiple pathways downstream of HOXB4 could be primary or
secondary changes related to HOXB4 overexpression.
1.6 Role of HOXB4 in Hematopoietic Stem and Progenitor Cell Expansion
Hematopoietic stem cells or repopulating cells are able to self-renew and
differentiate into cells of all hematopoietic lineages, and because of this unique
property, hematopoietic stem cells have been used for stem cell transplantation
and gene therapy applications. However, the inability to expand hematopoietic
stem cells has been a significant limitation for clinical applications. To date, the
most successful hematopoietic stem cell expansion method involves the
overexpression of the HOXB4 gene.145;146
1.6.1 Overexpression of HOXB4 In Vivo
Retroviral-mediated overexpression of HOXB4 enhances hematopoietic
repopulation, through the increased self-renewal of hematopoietic stem
cells.90;95;147 Serial transplantation studies revealed a greatly enhanced ability of
HOXB4-transduced bone marrow cells to regenerate the most primitive
hematopoietic stem cell compartment, resulting in 50 fold higher numbers of
transplantable totipotent hematopoietic stem cells in primary and secondary
recipients (Figure 1-6).95;145 After transplantation into primary recipient mice,
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Figure 1-6. HOXB4 induces expansion of hematopoietic stem cells in vivo.
Reprinted with permission from Nature Publishing Group. Sorrentino BP. Clinical
strategies for expansion of haematopoietic stem cells. Nat.Rev.Immunol.
2004;4:878-888.
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there was a rapid regeneration to normal pretransplantation levels in the
numbers of hematopoietic progenitors and mature blood cells in the mice
transplanted with control vector-transduced bone marrow cells, whereas
hematopoietic stem cell numbers recovered to only 5% to 10% of normal levels.
This finding demonstrates that hematopoietic stem cells were significantly
restricted in their self-renewal activity during the process of hematopoietic
repopulation (Figure 1-6).147 In contrast, HOXB4 vector-transduced cells were
capable of fully reconstituting the stem cell compartment, and resulted in a 14
fold more hematopoietic stem cells than the control-transduced bone marrow
cells in primary transplant recipients. Furthermore, HOXB4-overexpressing
hematopoietic stem cells did not expand above the normal level observed in
unmanipulated mice, indicating that its overexpression did not override the
regulatory mechanisms that maintain normal hematopoietic stem cell pool
size.147
In addition, recovery of stem cell numbers in HOXB4 recipients was reported
to be extremely rapid, reaching 25% of normal by 14 days posttransplant, some
80 fold greater than that seen in control transplanted recipients.89 The heightened
in vivo expansion of HOXB4-overexpressing hematopoietic stem cells was not
associated with identifiable anomalies in the peripheral blood of the transplanted
mice.95;145;146 In a clinically relevant nonhuman primate model, HOXB4
overexpression in CD34+ cells was shown to dramatically promote expansion
and engraftment of short-term repopulating cells and a significant, but less
pronounced, expansion of long-term repopulating cells.148
1.6.2 Overexpression of HOXB4 In Vitro
In addition to its function in promoting stem cell expansion in vivo, HOXB4overexpression also confers stem cell expansion in bone marrow cell cultured in
vitro. Cultures of HOXB4 -transduced bone marrow cells resulted in rapid,
extensive, and highly polyclonal hematopoietic stem cell expansion, with over
1000 fold greater numbers of stem cells relative to control vector-transduced
cells, which instead undersewnt stem cell loss during a 14 day culture period with
a corresponding 40 fold net stem cell decrease relative to input levels (Figure
1-7).90 Importantly, those in vitro expanded cells retained full lympho-myeloid
repopulating ability and enhanced regenerative potential in vivo, indicating the
feasibility of achieving in vitro expansion of hematopoietic stem cells without
functional impairment in vivo.90 Enhanced proliferation of day 12 CFU-S and
immature mixed clonogenic progenitors in vitro was also documented in HOXB4overexpressing bone marrow cells.95;149
The cellular effects and mechanisms of HOXB4-induced cell expansion were
studied in vitro. HOXB4-overexpressing bulk bone marrow cells were reported to
show rapid dominance in mixed culture and shortened population doubling time
in vitro.89 HOXB4 overexpression in vitro resulted in a stabilization of the
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Figure 1-7. HOXB4 induces expansion of hematopoietic stem cells in vitro.
Reprinted with permission from Elsevier. Antonchuk J, Sauvageau G, Humphries
RK. HOXB4-induced expansion of adult hematopoietic stem cells in vitro. Cell
2002;109:39-45.
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proliferation rate, while the proliferation rate of control-transduced bone marrow
cultures gradually declined.150 In addition, HOXB4-overexpressing bone marrow
cells displayed a more homogenous morphology and contained increased
numbers of hematopoietic progenitor cells capable of generating primitive
colonies in vitro. In contrast, control-transduced bone marrow cells in long-term
cultures showed hallmarks of myeloid differentiation and a reduced secondary
colony forming activity.150
1.6.3 ES Cell Specification
HOXB4 also plays a role in the specification of hematopoiesis at the earliest
stages of development by enhancing the hematopoietic differentiation potential of
ES cells.146;151 Overexpression of HOXB4 in murine ES cell-derived primitive
progenitors combined with culture on hematopoietic stroma cells induced a
switch to the definitive hematopoietic stem cell phenotype.146 The induction of
differentiation was initiated with EB (embryoid body) formation, and subsequent
differentiation and maintenance of hematopoietic cells was achieved by coculture with OP9 cells.146 The transient overexpression of HOXB4 for only
several weeks in hematopoietic progenitor cells initiated conversion of progenitor
cells to immature transplantable stem cells.146 Leukocytes derived from ES cells
ectopically expressing HOXB4 were immunologically functional, implying the
potential use of ES cell-derived hematopoietic progenitor cells in the treatment of
hematologic and immunologic diseases.152 These results provide new evidence
implicating HOXB4 in the control of very early development of the hematopoietic
system.
1.6.4 Potential Toxicity of HOXB4 Overexpression
Ectopic HOXB4 expression was reported to have a concentration-dependent
effect on lineage differentiation in mouse and human hematopoietic cells. The
existence of threshold levels were suggested for HOXB4 activity that control the
differentiation and self-renewal behavior of hematopoietic stem and progenitor
cells.153 Enforced HOXB4 expression caused a significant reduction of erythroid
and myeloid progenitors and B lymphoid compartment in vitro and in vivo when
using a strong viral promoter for expression.154 Transducing CD34+ cells from
large animals including nonhuman primates, dogs, and humans with HOXB4retroviral vectors can cause increased colony formation ability in dog cells
compared to human peripheral blood, human cord blood, and baboon cells.155
High levels of HOXB4 overexpression resulted in immortalization of primitive
hematopoietic cells from mice and dogs; in contrast, the cells from monkeys and
humans were not immortalized due to the relative low expression level of
HOXB4.155 In differentiated ES cells ectopically expressing HOXB4 in vitro,
myeloid development can be enforced and T lymphoid development can be
suppressed over a wide range of expression levels of HOXB4.156 These findings
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suggest that the growth promoting effects of HOXB4 are critically dependent on
its expression levels, which can result in important species-specific differences in
potency. Based on these facts, the therapeutic window of HOXB4 expression
levels must be carefully defined before initializing clinical trials.
Retroviral vector-mediated insertional mutagenesis can occur with HOXB4
overexpression. Hematopoietic stem cell gene therapy has been used to treat
patients with a number of life-threatening diseases. However, some patients
have developed retroviral vector-mediated leukemia after treatment.157 Myeloid
leukemia was reported to occur in large animals (dogs and macaques) 2 years
after transplantation with HOXB4-overexpressing cells, but not in control
retroviral vector transplanted large animals.157 However, based on the activation
of nearby genes known to be involved in leukemogenesis, the integration sites
observed in the leukemic clones containing HOXB4 were very likely a
combination consequence of sustained in vivo proliferation through the activated
ongenes and expansion effects by HOXB4.157
When using short hairpin RNAs to knockdown HOXB4 expression in a cell line
from the leukemic cells, profound growth inhibition and cell death occurred with
downregulation of the HOXB4 transgene. This evidence indicates that HOXB4
overexpression using retroviral vectors can pose a significant risk of
leukemogenesis in large animals. Thus, safety issues related to HOXB4mediated gene therapy must be considered. Newer vectors based on lentivirus
are now available that may circumvent this limitation.158
1.6.5 Hoxb4 Knockout and Other Hox-Deficient Mice
As overexpression of HOXB4 leads to dramatic hematopoietic phenotypes, it is
a surprise that Hoxb4-/- mice show only a defect in mild hematopoietic stem cell
proliferation.159 In Hoxb4-/- mice, the cellularity in spleen and bone marrow, red
blood cell counts, and hemoglobin values were minimally reduced. However, the
hematopoietic lineage distribution was normal and in bone marrow and fetal liver,
only a mild reduction of hematopoietic stem and progenitor cell numbers were
found.159 The conclusion from this study was that Hoxb4 is not required for
generation of hematopoietic stem cells and steady state maintenance of
hematopoiesis.159 c-Kit+ fetal liver cells from Hoxb4-/- mice expressed higher
levels of several other Hoxb cluster genes than control wild type cells by
quantitative PCR assay, indicating that normal hematopoietic stem cell activity in
Hoxb4-/- mice might be due to a compensatory upregulation of other Hox genes.
In order to determine whether this hypothesis is true, the entire Hoxb cluster was
deleted.160 However, again, this did not lead to major defects in
hematopoiesis.160 Hoxb1-b9-/- fetal liver cells retained full competitive
repopulation potential and the ability to regenerate all myeloid and lymphoid
lineages.160 The gene expression profile in purified c-Kit+ Hoxb1-b9-/- fetal liver
cells revealed expression changes in Hoxa4, a11, and c4. Primitive
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c-kit+Scal1+Lin- hematopoietic stem and progenitor cells lacking Hoxb3 and
Hoxb4 also displayed impaired proliferative capacity in vitro and in vivo.122 As no
defects in homing were observed, a slower regeneration of mutant hematopoietic
stem cells was suggested. Furthermore, treatment with cytostatic drugs
demonstrated slower cell cycle kinetics of hematopoietic stem cells deficient in
Hoxb3 and Hoxb4, resulting in increased tolerance to antimitotic drugs.
In the Hoxa9-/-;b3-/-;b4-/- triple deficient mice, the reconstitution defect in hoxa9
deficient hematopoietic stem cells was not enhanced further in the triple deficient
cells. Therefore, none of these hox proteins was proved to play absolutely
essential role for generation or maintenance of all major blood lineages.161
Some other Hox knockout mice have been reported to show defects in
embryonic development. Hoxa4-/- or Hoxa6-/- mice showed homeotic
transformation of cervical vertebrae in development. However, defects were not
observed in other tissues that normally express these genes.162 Hoxc4 is a
mouse homeobox gene located at the 3' end of the HoxC cluster. Of the Hoxc
genes, Hoxc4 is expressed in the most anterior regions of the central nervous
system and prevertebral column. Hoxc4-/- mice were viable and fertile, and
various abnormalities in the cervical and thoracic regions were documented.163
However, no studies have been performed on the hematopoietic system yet.
Similarly, Hoxd4-/- mice also had defects in skeleton development with homeotic
transformations of the second cervical vertebrae (C2) to the first cervical
vertebrae (C1) and malformations of the neural arches of C1 to C3 and of the
basioccipital bone.164 These phenotypic similarities and differences between
Hoxd4 and previously reported Hoxa4, Hoxb4 and Hoxc4 deficient mice suggest
that Hox gene paralogs have both redundant and unique functions.
Pbx1, described above as a cofactor of Hox, is a homeodomain transcription
factor that was originally identified as the product of a proto-oncogene in acute
pre-B-cell leukemia, and is also a global regulator of embryonic development.
Pbx1 and a subset of homeodomain proteins collaboratively bind to DNA as
molecular complexes with potential consequences for mammalian development.
Due to embryonic lethality in its absence, caused by severe hypoplasia or aplasia
of multiple organs and widespread patterning defects of the axial and
appendicular skeleton,165;166 Pbx1-/- embryonic stem cells were studied instead
and failed to generate common lymphoid progenitors, resulting in a complete lack
of B and NK cells, and a partial impairment of T-cell development in transplanted
mice.165 B-cell development was rescued from common lymphoid progenitors
following restoration of Pbx1 expression in its deficient ES cells. This critical
functions of Pbx1 occured at a stage between hematopoietic stem cell
development and B cell commitment as one earliest-acting transcription factor to
regulate de novo B lineage lymphopoiesis.165
With the information generated from Hox deficient mice, it seems like no single
Hox gene plays an essential physiological role in hematopoiesis maintenance or
hematopoietic stem cell generation. Instead, a redundant network of genetic
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interactions between different Hox genes in primitive hematopoietic cells is most
likely. It was recently reported that Hoxb4 and its other three paralogs: Hoxa4,
Hoxc4 and Hoxd4 had the similar effect in promoting hematopoietic stem and
progenitor cells expansion in vitro.167 Our lab also demonstrated that when
overexpressed in bone marrow cells, HOXA4, B4, C4 and D4 showed similar
effect in promoting engraftment in the transplanted mice (Figure 1-8). This
redundancy may explain the mild defect phenotype in Hoxb4-/- mice,158 and
suggests that Hox4 paralogs may be required in hematopoiesis and
hematopoietic stem cell functions.
1.6.6 Mechanisms of HOXB4 Function
Although it is well-known that enforced expression of HOXB4 can induce stem
cell self-renewal and expansion. Relatively little is know about the molecular
mechanisms by which this occurs. Key domains in the HOXB4 protein were
mutated to investigate their roles in protein function and stem cell expansion.140
The in vitro and in vivo expansion capacity of DNA-binding HOXB4 mutants was
completely lost, indicating that HOXB4 must bind DNA in order to promote selfrenewal.140 In contrast, a point mutation in “YPWM” motif, which disrupts Pbx
cofactor binding, still conferred a pronounced in vitro expansion advantage in
transduced bone marrow populations, and those cells also showed dramatically
enhanced regenerative potential in vivo.140 This finding suggests that the
capacity of HOXB4 to induce hematopoietic stem and progenitor cell expansion
is DNA-binding dependent but does not require direct Hox and Pbx interaction. In
another report, when Pbx expression was knocked down in HOXB4
overexpressing bone marrow cells, the hematopoietic stem cell generation ability
was >20 times more competitive than the wild type cells overexpressing
HOXB4.168 Furthermore, the myeloid and lymphoid lineage differentiation activity
and the hematopoietic stem cell pool were normal in vivo in mice transplanted
with Pbx knocked down cells.168 This result suggests the existence of a distinct
mechanism that limits the expansion of HOXB4 transduced hematopoietic stem
cells in mice.168;169
The specific mechanisms by which HOXB4 promotes hematopoietic stem cell
expansion are still a mystery. No direct targets of HOXB4 have been defined in
vivo or even in primary cells so far. Although as discussed above, the TNF-α
pathway was recently shown to be downstream of HOXB4, using gene
expression profiling in long-term cultured bone marrow cells. However, it is
unclear whether any of the genes on this pathway are direct transcriptional
targets of HOXB4.144
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Figure 1-8. Redundancy of HOX4 paralogs in promoting hematopoietic
stem and progenitor cell expansion. Flow cytometry-detected GFP percentage
of the peripheral blood cells from 12 weeks-transplanted mice with bone marrow
cells transduced by MSCV-HOX4-IRES-GFP or MSCV-IRES-GFP control
vectors. Gr and Mac: markers for rapid turnover myeloid cells.
Source: Unpublished data receieved from Brian.P. Sorrentino’s lab on October
1st, 2009.
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1.7 Hemgn
1.7.1 Expression Pattern and Biochemical Characteristics of Hemgn
In my study, I have focused on a new target gene of HOXB4 in hematopoietic
cells called Hemogen (Hemgn) or EDAG. Hemgn is a recently discovered
nuclear protein and expresses in testis and hematopoietic tissues; specifically, it
is highly expressed in hematopoietic stem and progenitor cells and is
downregulated as hematopoietic cells differentiate.170 The expression of Hemgn
during embryogenesis shows a spatial and temporal pattern corresponding to the
ontogeny of hematopoiesis. The expression switches from yolk sac blood islands,
to fetal liver hematopoietic cells during embryogenesis to bone marrow and
spleen in adult mice.170 In adult mouse tissues, Hemgn mRNA expression is
restricted to spleen and bone marrow cells (Figure 1-9A). In bone marrow cells,
relatively high levels of Hemgn mRNA were detected in Linloc-kit+ Scal1+, CD34+,
and Lin- hematopoietic stem and progenitor cell populations (Figure 1-9B).170 In
adult mouse spleen, Hemgn was expressed specifically in the erythrocytes red
pulp regions but not in the white pulp which contains B and T lymphocytes
(Figure 1-9C).170 Immunostaining studies showed that Hemgn was localized in
nuclei and absent in the cytoplasm (Figure 1-9D).170 Moreover, hemgn is also
expressed in testis in a variant splice form using an alternative promoter,
suggesting a complex transcriptional regulation.171
A human homolog of Hemgn, HEMGN, also called EDAG, maps to
chromosome 9q22, which contains a cluster of important genes involved in
hematopoiesis. The expression pattern of EDAG is similar to its mouse
homolog.172 Like Hemgn, EDAG exhibited specific expression in human
hematopoietic cells in the adult bone marrow and fetal liver. No EDAG transcripts
were detected in peripheral blood cells or other non-hematopoietic tissues, such
as adult liver, heart, brain, skeletal muscle, kidney, spleen, pancreas, tonsil, and
colon.172
Sequence analysis shows that Hemgn and EDAG contain a nuclear
localization motif and a coiled-coil domain, but no other recognizable protein
motifs. At the nucleotide level, human and mouse Hemgn homologs show 43%
identity, although the sequence conservation between the nuclear localization
signal and the coiled-coil domains are higher. Coiled-coil domains of a protein
are protein-protein interaction domains containing multiple α-helices twisting
around each other to form a supercoil. A protein containing coiled-coil domains
can usually interact with other coiled-coil proteins for protein-protein recognition
and interaction.
Based on the nuclear localization of EDAG, the role of EDAG as a
transcription factor has been investigated.173 Using an yeast and mammalian
two-hybrid system, it was suggested that that EDAG has transactivation
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Figure 1-9. Expression and localization of Hemgn. (A) Northern blotting for
mRNA of Hemgn in indicated tissue. A 2.4 kb message was detected in the
spleen and bone marrow. (B) RT-PCR detected mRNA expression of Hemgn in
indicated tissue. (C) By hybridization with antisense RNA probe, Hemgn
transcripts were localized in the red pulp (rp) but not in the white pulp (wp) in
mouse spleen. (D) The Hemgn-FLAG fusion protein was transfected into COS-7
cells and detected with anti-FLAG antibody. The signal was localized in the cell
nuclei (nu) but not in the nucleoli (no) or cytoplasm (cy).
Reprinted with permission from Elsevier. Yang LV, Nicholson RH, Kaplan J, Galy
A, Li L. Hemogen is a novel nuclear factor specifically expressed in mouse
hematopoietic development and its human homologue EDAG maps to
chromosome 9q22, a region containing breakpoints of hematological neoplasms.
Mech.Dev. 2001;104:105-111.
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activity, indicating that EDAG could be a transcriptional regulator.173 EDAG cDNA
fused with the Gal4 DNA-binding domain (DBD) was transformed into yeast cells
and found to transcriptionally activate a chromosomally integrated lacZ reporter
gene. This result was also confirmed in mammalian cells through luciferase
assay.
1.7.2 Functions of Hemgn
EDAG expression is very high in leukemia cell lines such as K562, HEL and
Mo7e and megakaryoblast leukemia cell lines DAMI, MEG-01.174 Moreover,
overexpression of EDAG has been reported in a variety of human leukemia and
lymphoma cells,175 suggesting that EDAG may play a role in hematopoietic
transformation and leukemogenesis.
Enforced expression of EDAG in hematopoietic cell lines increased
proliferation, enhanced survival, and inhibited differentiation.172 Overexpression
of EDAG in NIH3T3 cells results in malignant transformation of cells, as
characterized by cell morphology, anchorage-independent growth and
tumorigenicity in nude mice.176 Overexpression of EDAG in HL-60 cells blocked
monocyte and macrophage differentiation after pentahydroxytiglia myristate
acetate induction.172 Overexpression of EDAG in pro-B Ba/F3 cells prolonged
survival and increased the expression of c-Myc, Bcl-2 and Bcl-xL in the absence
of IL-3.172 In contrast, downregulation of EDAG protein in K562 cells inhibited
growth and colony formation, and enhanced sensitivity to erythroid differentiation
induced by hemin.172 EDAG was shown to enhance the transcriptional activity of
NF-kB (nuclear factor kappa B), and DNA-binding activity of NF-kB was
sustained in Ba/F3 cells overexpressing EDAG after IL-3 withdrawal. Inhibition of
NF-kB activity resulted in promoting EDAG-induced Ba/F3 cell death.172 These
results indicate that EDAG can block apoptosis, possibly through the activation of
NF-kB.172 These results suggest that EDAG is an important regulator for
proliferation and differentiation of hematopoietic cells, making its involvement in
the HOXB4 phenotype very interesting.
An EDAG transgenic mouse was generated, using the human CD11a
promoter to selectively express EDAG in hematopoietic tissues.173 EDAG
overexpression in transgenic mice resulted in disrupted hematopoietic
homeostasis. Myelopoiesis was enhanced with a progressive myeloid
hyperplasia in the spleen and increased peripheral blood granulocytes in
circulation. Lymphopoiesis was severely inhibited in the transgenic mice with B
lymphopoiesis blocked at the transition from pro/pre-B I to pre-B II stage in the
bone marrow. Thymocyte development was also blocked at the most immature
double negative stage. These data suggest that EDAG can act as a key regulator
in primitive hematopoietic cells and its downregulation during maturation of blood
cells may be necessary for maintaining homeostasis of the hematopoietic
lineages. In the same report, EDAG was shown to be a transcriptional regulator
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which had transactivation activity and regulated the expression of several key
transcription factors such as PU.1 and Pax5 in transgenic hematopoietic stem
cells,173 suggesting that EDAG may positively or negatively regulate transcription
of specific target genes. However, whether the effect of EDAG on these genes is
direct needs further determination, since there is no evidence now that EDAG
can bind DNA directly.
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CHAPTER 2. IDENTIFICATION OF EARLY AND POTENTIAL
DIRECT TARGET GENES OF HOXB4 USING AN INDUCIBLE
HOXB4-ERT2 SYSTEM
2.1 Summary
In order to understand the mechanism of HOXB4 mediated expansion of
hematopoietic stem cells, we focused on identifying early and direct
transcriptional targets of HOXB4 in primary murine hematopoietic progenitor
cells. For this purpose, a HOXB4-ERT2 fusion protein was created by molecular
subcloning and introduced into undifferentiated bone marrow cells. Twelve hours
after tamoxifen (TAM) exposure, HOXB4-ERT2 transduced cells were functionally
evaluated in myeloid progenitor expansion assays. Extracted RNA was analyzed
by Affymetrix 430V2 chips, comparing expression patterns in HOXB4-ERT2
versus GFP control vector-transduced cells. Four biologically independent
experiments were performed to assess reproducibility. Stringent criteria were
applied for mining microarray data using bioinformatics algorythms. Seventy
seven probesets were identified that were differentially expressed (>1.5 fold,
paired t-test p<0.01) in this early response to HOXB4 induction and were
prioritized as candidate targets. Quantitative PCR was performed to validate the
microarray data for specific genes of interest.
2.2 Introduction
Transcriptional regulation of gene expression is an essential function in all
eukaryotes and is central to complex developmental control. Transcription factors
are proteins that can regulate the expression of many physiologically important
target genes including those that regulate proliferation and differentiation. The
identification of transcription factors, transcription factor-target genes and
transcriptional regulatory networks is therefore of fundamental importance in
biology, because unraveling the logic of these gene regulation networks is
necessary for a complete understanding how transcription factors contribute to
biological phenotype. In my study, identifying molecules that promote
hematopoietic stem cell expansion is a central goal, since significant expansion
of hematopoietic stem cells would allow new transplant-based therapies.3;91
However, in vitro expansion of hematopoietic stem cells has been difficult to
achieve and often results in differentiation and apoptosis of developmentally
primitive hematopoietic cells. Human HOXB4, a member of the homeobox
transcription factor family, can promote hematopoietic stem and progenitor cell
expansion both in vivo and in vitro when ectopically expressed in murine bone
marrow cells.90;95 HOXB4 overexpression also promotes specification of definitive
hematopoietic stem cells from differentiating murine embryonic stem cells.146;156
Since very little is known about the mechanisms of how HOXB4 promotes
expansion of hematopoietic stem and progenitor cells, and because no specific
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direct target genes have yet been identified in hematopoietic cells, one objective
of this study was to identify the downstream genetic pathways of HOXB4. In
addition, direct target identification could also provide new factors for promoting
hematopoietic stem and progenitor cell expansion.
There is only one published report identifying the targets of HOXB4 in
hematopoietic cells.144 In this report, the downstream pathways of ectopic
expressed HOXB4 were studied. Gene expression profiling assays were
performed using enriched adult hematopoietic stem cells and embryonic
derivatives that had been transduced with an inducible form of HOXB4. A set of
overlapping gene expression change was generated from these two cellular
systems and selected to represent common targets of HOXB4.144 These results
showed that HOXB4 protected adult hematopoietic stem cells from the inhibitory
effects mediated by the proinflammatory cytokine tumor necrosis factor alpha
(TNF-α), which likely inhibits the competitive repopulation advantage in the
absence of HOXB4 overexpression.144 It was also demonstrated that HOXB4
activity and FGF signaling were related, since HOXB4-mediated expansion of
adult and ES cell-derived hematopoietic stem cells was enhanced by inhibition of
FGF receptors.144 In this report, however, no evidence was provided to show that
any target genes from the generated candidate list was a direct transcriptional
target of HOXB4. It was not clear if these pathway effects were primary versus
secondary effects. Instead, their data suggest that multiple pathways
downstream of HOXB4 could be regulated and they intertwined to modulate the
self-renewal of hematopoietic stem cells promoted by HOXB4.
In my study, I utilized a traditional method for identifying the target genes of
HOXB4 by an unbiased screen of its potential targets in a large scale gene
expression profile analysis. Indeed, the activity of many nuclear localized
proteins can be induced with hormones when these proteins are fused to
hormone binding domains of steroid receptors such as estrogen receptor (ER).
This allows pulsing of activity and enables study of acute effects. We established
a HOXB4-ERT2 inducible system to regulate the activity of HOXB4 in transduced
hematopoietic cells by controlling the nuclear entry of HOXB4 with exogenous
application of tamoxifen. When tamoxifen is absent, the HOXB4-ERT2 fusion
protein is sequestered by HSP90 in the cytosol. When tamoxifen is added, it
diffuses into cells and binds to the ligand binding domain of ERT2 and thus
releases the fusion protein from HSP90, which then can translocate into the
nucleus and regulate the cis- elements of downstream genes for their activation
or repression. Although the function of HOXB4 is most important in
hematopoietic stem cell expansion, it also has a profound effect on
hematopoietic progenitor cell expansion. It is relatively difficult to purify enough
hematopoietic stem cells for microarray screening analysis, and there exists an
established simple in vitro assay for evaluating HOXB4 function in hematopoietic
myeloid progenitor cell expansion promptly.95 Therefore, I used this assay as a
surrogate for hematopoietic stem cells in this study of HOXB4 downstream target
identification.
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2.3 Materials and Methods
2.3.1 Vector Construction
Generation of MSCV-IRES-GFP vector was described previously.177 The
human HOXB4 cDNA95 was kindly provided by Dr. Keith Humphries (Terry Fox
Laboratory, Vancouver, Canada), and was cloned upstream of the IRES cassette
into MSCV-IRES-GFP177;178 backbone. For the MSCV-HOXB4-ERT2-IRES-GFP
vector, the mutated ligand binding domain of estrogen receptor (ERT2) was fused
to the C-terminus of the HOXB4 cDNA with a linker with the following sequence:
CLQNSDQRNE. The fusion HOXB4-ERT2 gene was then cloned into the EcoRI
and XhoI sites of MSCV-IRES-GFP vector.
2.3.2 Retroviral Vector Preparation
A polyclonal population of ecotropic retroviral producer GPE+86 cells179 was
generated using a previously described approach.180;181 Briefly, 2 µg pCAGGSVSVG and 4 µg pEQ-PAM3(-E) helper plasmids were co-transfected with 4 µg
MSCV-cDNA-IRES-GFP vector into 8x106 cycling 293T cells using FuGENE 6
reagent (Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s instructions. Retroviral vector supernatants were harvested 48
hours post transfection, pooled, filtered through 0.45 µm PVDF filter (Millipore,
Billerica, MA), and used for transducing the cycling GPE+86 cells in the presence
of 6 µg/ml polybrene. The transduced GFP positive GPE+86 cells were sorted
and expanded in culture for establishing stable retroviral vector producer lines.
The helper-free recombinant retroviral vector supernatants freshly collected from
the GPE+86 producer cells were filtered through 0.45 µm pore filter for
transducing bone marrow cells.
2.3.3 Separation, Transduction of Lin- Bone Marrow Cells and Analysis
Bone marrow cells were harvested from the tibias and femurs of 7 to 12 weeks
old female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) as
previously described,182 and were incubated with phycoerythrin (PE)-conjugated
lineage antibody mixture (anti-mouse Mac-1, Gr-1, B220, CD4, CD8, Ter-119,
Pharmingen, BD Biosciences, Franklin Lakes, NJ). Lin- bone marrow cells were
enriched by depleting PE-labeled cells through anti-PE magnetic microbeads
(Miltenyi Biotec, Auburn, CA) on autoMACSTM separator (Miltenyi Biotec)
according to the manufacturer’s instructions. The Lin- bone marrow cells were
prestimulated for 2 days with 20 ng/ml recombinant mouse IL-3, 50 ng/ml human
IL-6, and 50 ng/ml mouse SCF (R&D Systems, Minneapolis, MN) in Dulbecco's
modified Eagle medium (DMEM) supplemented with 15% fetal bovine serum
(FBS), 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine (R&D
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systems, Minneapolis, MN). The cells were then centrifuged at 2000 rpm for 30
minutes at room temperature by using plates preloaded with 25 µg/ml
RetroNectin (Takara, Madison, WI) and retroviral vector supernatant generated
as described above at an multiplicity of infection (MOI) of 10 to 20. After 3 to 4
rounds of transduction in 2 consecutive days, cells were collected, washed with
PBS, and then resuspended in the cytokine-supplemented medium described
above. Proportions of the transduced GFP positive cells were determined by flow
cytometry. Cells were cultured in the presence of TAM for additional time before
plating into methylcellulose media for CFU-C assay,95 and RNA extraction for
microarray.
2.3.4 TAM Induction of HOXB4-ERT2 and Myeloid Progenitor Assays
15.2 mg of tamoxifen citrate (equivalent to 10 mg of tamoxifen-TAM) tablet
(Barr Laboratories, Pomona, NY) was dissolved in 20 ml ddH2O to obtain the
stock 0.5 mg/ml TAM solution. The TAM solution was added directly into the
bone marrow cells culture medium at the concentration 300 nM. TAM was
withdrawn, and cells were plated for myeloid progenitor CFU-C assays
established for HOXB4 expansion activity as previously described.95 In details,
bone marrow cells were plated at 500 cells/ml in into MethoCult GF M3434
methylcellulose medium (StemCell Techologies, Vancouver, BC, Canada)
containing various cytokines supporting growth of clonogenic myeloid progenitor
cells. After 7 days, primary (1°) colonies were scored, collected, resuspended,
and re-plated at 105 cells/ml density into the M3434 methylcellulose medium for
10 days culture. The generated secondary (2°) colonies were scored to
quantitate the expansion of myeloid progenitors.
2.3.5 Western Blotting
Whole cell extracts were prepared from GPE+86 cells by M-PER Mammalian
protein extraction reagent (Pierce, Thermo Scientific, Rockford, IL) supplemented
with the protease inhibitors (HaltTM protease inhibitor cocktail kit, Thromo
Scientific, Rockford, IL; Pefabloc SC Plus, Roche Applied Science, Indianapolis,
IN). The proteins were then resolved on a 4-12% gradient NuPAGE Bis-Tris gel
(Invitrogen, Carlsbad, California) and transferred to 0.45 μm PVDF membrane.
The primary monoclonal antibody (clone I12) (The Developmental Studies
Hybridoma Bank, the University of Iowa, Iowa City, IA) was used for HOXB4 and
HOXB4-ERT2 detection.
2.3.6 Immunofluorescence Staining
1x105 Lin- bone marrow cells were cytospined and fixed in 3.7% formaldehyde
for 30 minutes at room temperature, washed and permeabilized in 1% Triton X-
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100 for 5 minutes at room temperature. Anti-HOXB4 antibody (clone I12) was
added at 37ºC for 1 hour, and after PBS washing, secondary antibody Alexa
Fluor 594 goat anti-rat IgG(H+L) (Invitrogen, Carlsbad, California) was added to
the cells for at room temperature for 1 hour. The nucleus was stained with
TOTO-1 iodide (Invitrogen, Carlsbad, California). The stained slides were imaged
with a Nikon TE2000-E inverted microscope equipped with a C1Si confocal
system and an X40 Plan Apo objective.
2.3.7 RNA Isolation, Affymetrix Array Hybridization and Analysis
Total RNA was extracted from TAM-treated Lin- bone marrow cells using RNA
STAT-60TM reagent (Tel-Test, Friendswood, TX) according to the manufacturer's
instructions. The RNA concentration and purity was determined by
spectrophotometric analysis, integrity was confirmed by electrophoresis analysis
using Agilent 2100 Bioanalyzer Lab-on-a-chip system (Agilent Technologies,
Santa Clara, CA). Total RNA (100 ng) was processed in the Hartwell Center
microarray core according to the Affymetrix eukaryote two-cycle target labeling
protocol
(http://www.affymetrix.com/support/technical/manual/expression_manual.affx).
Biotin-labeled cRNA (20 µg) was hybridized overnight at 45°C to the Mouse430v2 GeneChip array. After staining and washing, arrays were scanned and
expression values were summarized using the MAS5 algorithm as implemented
in the GCOS v1.4 software (Affymetrix, Santa Clara, CA). Signals were
normalized for each array by scaling to a 2% trimmed mean of 500. Detection
calls (Present, Absent and Marginal) were determined using the default
parameters of the software. Signal values were log2-transformed prior to
analysis. Differential expression between HOXB4-ERT2 transduced and GFP
only-transduced cells was determined from four independent experiments using
the paired t-test (S-Plus 6.2 software, TIBCO, Palo Alto, CA). Hierarchical
clustering was performed using the Spotfire DecisionSite 9.0 software (TIBCO,
Palo Alto, CA). Probeset annotations were obtained from the Affymetrix website
(http://www.affymetrix.com/analysis/index.affx).
2.3.8 Gene Expression Validation
The RNA was first reversely transcribed with SuperScriptTM III First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, California) by using oligodT primers. All gene-specific PCR primers were ordered from Quanti Tect Primer
Assay kit (Qiagen, Valencia, CA) (Table 2-1).
The real-time PCR reactions were performed using QuantiTectTM SYBR Green
PCR kit (Qiagen, Valencia, CA) following the manufacturer's instructions. The
relative expression of each candidate gene was performed at least in triplicate
and calculated using the comparative quantitative comparative CT (2-∆∆CT)
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Table 2-1. The ordered gene-specific PCR primers used in real-time PCR
validation analysis.
Gene
Symbol
Gapdh
Actb
Thy1
Ephx2
Slc22a3
Hemgn
Ms4a4c
Pltp
Mettl1
Cldn11

QuantiTect Primers

Cat. No.

Mm_Gapdh_3_SG QuantiTect Primer Assay
Mm_Actb_2_SG Quanti Tect Primer Assay
Mm_Thy1_1_SG QuantiTect Primer Assay
Mm_Ephx2_1_SG QuantiTect Primer Assay
Mm_Slc22a3_1_SG QuantiTect Primer Assay
Mm_Hemgn_1_SG QuantiTect Primer Assay
Mm_Ms4a4c_1_SG QuantiTect Primer Assay
Mm_Pltp_2_SG QuantiTect Primer Assay
Mm_Mettl1_1_SG QuantiTect Primer Assay
Mm_Cldn11_1_SG QuantiTect Primer Assay

QT01658692
QT01136772
QT00245287
QT00109165
QT00131894
QT00106099
QT00175763
QT01053311
QT00153433
QT00104195
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method with normalization to Gapdh internal control. The PCR primers of Actb
were used for normalization in the real-time PCR reactions for detecting Hemgn
expression in Hoxb4-/- and wild type (WT) mice.
2.4 Results
2.4.1 Retroviral Constructs and Expression of HOXB4-ERT2 Fusion Protein
To identify early and direct transcriptional targets of HOXB4 in murine bone
marrow cells, a HOXB4-ERT2 fusion gene was developed to allow temporally
regulated HOXB4 activity by TAM.183 As controls, I used a retroviral vector
expressing GFP protein as negative control, HOXB4 wild type gene as positive
control under control of the MSCV promoter (Figure 2-1A). Expression of HOXB4
or HOXB4-ERT2 fusion protein were verified in established virus producer
GPE+86 cells using western blotting analysis (Figure 2-1B).
2.4.2 TAM Inducible Nuclear-Translocation of HOXB4-ERT2
To test whether HOXB4-ERT2 fusion protein can translocate into the nucleus
after TAM treatment, TAM was added into the cultures of Lin- bone marrow cells
at a concentration 300 nM for different time periods. TAM-induced nuclear
translocation of HOXB4-ERT2 in transduced Lin- bone marrow cells was
confirmed by immunofluorescence staining 6 hours after TAM treatment (Figure
2-2). This experiment showed no nuclear localization of HOXB4 in the absence
of TAM, implying that function would not be “leaky” in the absence of induction.
2.4.3 TAM Inducible HOXB4-ERT2 Activity Promoted Hematopoietic
Progenitor Cell Expansion In Vitro
An established expansion assay for myeloid progenitors was utilized for
verifying TAM-dependent function.95 Lin- bone marrow cells were purified and
transduced with the HOXB4-ERT2 vector or the control GFP vector. The
transduced cells were exposed to 300 nM TAM in the culture medium for 12, 24,
and 48 hours, washed, and then plated into semi-solid methylcellulose medium
for myeloid progenitor colony forming unit cells (CFU-Cs) assay (Figure 2-3).
TAM treatment for only 12 hours resulted in the generation of larger myeloid
colonies, and more importantly, resulted in an increase in secondary colony
number after re-plating (Figure 2-4A and B). Fluorescent microscope studies
verified that the majority of secondary colonies were GFP positive and therefore
contained and expressed the vector (Figure 2-5). These results prove that
activation of HOXB4-ERT2 by TAM resulted in expansion of myeloid progenitor
cells in vitro. This experiment also verified that no myeloid expansion occurred in
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Figure 2-1. Retroviral constructs and expression of HOXB4 and HOXB4ERT2 protein. (A) cDNA of HOXB4 and HOXB4-ERT2 was cloned upstream of
the IRES cassette in MSCV-IRES-GFP backbone; The mutated ligand binding
domain of estrogen receptor (ERT2) was fused to the C-terminus of the HOXB4
cDNA with a linker CLQNSDQRNE. (B) Overexpression of HOXB4 or HOXB4ERT2 was confirmed in retroviral vector producer GPE+86 cells by western
blotting with a monoclonal anti-HOXB4 antibody (clone I12).

36

Figure 2-2. TAM-induced cytosol to nucleus translocation of HOXB4-ERT2 in
Lin- bone marrow cells confirmed by confocal microscopy. Red: HOXB4ERT2; Blue: nucleus dye.
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Figure 2-3. Schematic illustration of myeloid progenitor secondary CFU-C
expansion assays.

38

Figure 2-4. Effect of TAM-induced HOXB4-ERT2 activity in vitro. (A) TAM
treatment for 12, 24 and 48 hours induced increase in secondary myeloid
progenitor colony formation in HOXB4-ERT2-overexpressing Lin- bone marrow
cells in vitro. (B) Pictures of the secondary myeloid progenitor colony plates from
HOXB4-ERT2-overexpressing cells treated with TAM for 0, 12, 24 and 48 hours.
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Figure 2-5. Secondary myeloid progenitor colonies from HOXB4-ERT2
overexpressing Lin- bone marrow cells were GFP positive under
fluorescence microscopy.
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the absence of TAM, given that secondary CFU-C colony formation was low and
equivalent to that seen with the GFP-only negative control vector.
2.4.4 Identification of HOXB4 Early Downstream Targets by Expression
Microarrays
To identify early and direct downstream HOXB4 target genes involved in
expansion of hematopoietic progenitor cells, RNA was extracted 12 hours after
TAM-treatment of Lin- bone marrow cells transduced with either the HOXB4-ERT2
vector or with the GFP control vector, and was analyzed for differential gene
expression using Affymetrix 430v2 chips (Figure 2-6). The transduction efficiency
ranged from 60% to 70% in multiple experiments. Analysis of 4 independent
transduction experiments showed good reproducibility in gene expression
changes. The pearson correlation coefficient between all experimental samples
ranged from 0.91 to 0.97 among probesets with more than one “Present” calls
(Table 2-2), indicating that there was low experimental variation and that HOXB4
overexpression did not cause a change in global gene expression. First, we
manually excluded those probesets showing more than 4 “Absent” calls in a total
of 8 samples from the 4 experiments. A probeset was considered a potential
downstream target of HOXB4 if the difference between the 2 mean expression
values (HOXB4-ERT2 vs. GFP) was at least 1.5 fold change, and the extent of
the expression difference was statistically significant (p<0.01) as evaluated by
paired t-test method. We chose a 1.5 fold threshold due to the fact that 30~40%
of the cells in a given sample were not transduced, hence the 1.5 fold change
measured from the samples would underestimate what actually occurred in the
transduced cells.
Seventy seven probesets were identified as being significantly changed by this
analysis. Among them, 44 were upregulated (Table 2-3), and 33 were
downregulated (Table 2-4) by HOXB4 induction. Hierarchical clustering analysis
and heat map was generated for these 77 probesets from the 4 independent
experiments (Figure 2-7 and Figure 2-8). Functional classification of those
probesets by Gene Ontology annotations denoting different biological processes
(Figure 2-9) showed a relatively high percentage of probesets involved in
metabolism (20, 17%), signal pathways (15, 13%), and development and
differentiation (14, 12%).
2.4.5 Validation of the Selected HOXB4 Target Genes
To validate the expression change seen in the microarray assays with HOXB4
induction, eight genes which showed a relatively large change in expression
were selected for quantitative real time-PCR confirmation (Figure 2-10).
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Figure 2-6. Schematic illustration of the inducible HOXB4-ERT2 system for
target screening in Lin- bone marrow cells.
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Table 2-2. Pearson correlation coefficients between the 8 experimental
samples with probesets >1 present call in microarray.
Array
Exp1
GFP
Exp1
HOXB4T2
ER
Exp2
GFP
Exp2
HOXB4T2
ER
Exp3
GFP
Exp3
HOXB4T2
ER
Exp4
GFP
Exp4
HOXB4T2
ER

Exp1 Exp1 Exp2 Exp2 Exp3 Exp3 Exp4 Exp4
GFP HOXB4- GFP HOXB4- GFP HOXB4- GFP HOXB4T2
T2
T2
T2
ER
ER
ER
ER
0.95
0.95

0.94

0.94

0.95

0.94

0.92

0.91

0.94

0.94

0.94

0.95

0.94

0.93

0.94

0.94

0.94

0.93

0.92

0.94

0.93

0.92

0.91

0.95

0.94

0.93

0.95

0.95

0.94

0.94

0.94

0.94

0.94

0.95

0.94

0.94

0.94

0.94

0.95

0.94

0.93

0.95

0.92

0.94

0.93

0.92

0.94

0.95

0.91

0.93

0.92

0.91

0.93

0.95
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0.95
0.95

Table 2-3. The 44 probesets upregulated by HOXB4-ERT2 .

Probeset

Gene
Symbol

Fold
Chng

1421244_at
1445285_at

Esr1
14.42
9230107O19 2.47

1423135_at Thy1
1448499_a_at Ephx2

2.34
2.25

1437260_at
1420444_at

Mmrn1
Slc22a3

1.94
1.91

1460130_at
1418199_at
1459262_at
1425506_at

EG433632
Hemgn
Mterfd1
Mylk

1.90
1.85
1.80
1.80

1429642_at

Anubl1

1.79

1446745_at EG433637
1419550_a_at Stk39

1.78
1.78

1436419_a_at 1700097N02 1.77
Rik
1446470_at ENSMUSG0 1.77
0000045520
1441747_at A330024P14 1.76
Rik
1422317_a_at Il1rl1
1.75
1421182_at Clec1b
1.73
1435594_at

Arl6ip2

1.71

1417872_at
1418892_at

Fhl1
Rhoj

1.70
1.69

1429691_at

5430405N12 1.66
Rik

Paired tTest p
Gene Description
Value
5.56E-04 estrogen receptor 1 (alpha)
7.77E-03 Similar to histamine receptor H
3
8.99E-03 thymus cell antigen 1, theta
4.85E-03 epoxide hydrolase 2,
cytoplasmic
6.56E-03 multimerin 1
3.74E-03 solute carrier family 22,
member 3
4.95E-05 predicted gene, EG433632
8.05E-03 hemogen
9.14E-03 MTERF domain containing 1
7.37E-03 myosin, light polypeptide
kinase
4.35E-03 AN1, ubiquitin-like, homolog
(Xenopus laevis)
5.59E-03 predicted gene, EG433637
8.12E-03 serine/threonine kinase 39,
STE20/SPS1 homolog (yeast)
5.82E-03 RIKEN cDNA 1700097N02
gene
6.65E-03 predicted gene,
ENSMUSG00000045520
5.30E-03 RIKEN cDNA A330024P14
gene
2.60E-03 interleukin 1 receptor-like 1
1.38E-03 C-type lectin domain family 1,
member b
9.15E-03 ADP-ribosylation factor-like 6
interacting protein 2
9.35E-03 four and a half LIM domains 1
1.12E-04 ras homolog gene family,
member J
1.07E-03 RIKEN cDNA 5430405N12
gene
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Table 2-3. Continued.
Gene
Symbol

Fold
Chng

Tdrd3
LOC552901
4930438A08
Rik
Gstt1

1.65
1.65
1.63

Paired tTest p
Value
5.62E-03
8.95E-03
6.62E-03

1.62

5.36E-03

Apln
1.61
1700086O06 1.60
Rik
1438575_a_at 3974589
1.60
1444869_at H3145H06 1.60
1422927_at Yipf7
1.60
1442884_at Hgf
1.58
1435710_at AI661384
1.58
1430522_a_at Vamp5
1.57

2.22E-03
7.26E-03

1440227_at

Slc5a3

1.57

9.71E-03

1439755_at

Sipa1l1

1.55

3.44E-03

1438664_at

Prkar2b

1.54

2.84E-03

1444433_at
1420688_a_at
1457110_at
1450235_at

30077393
Sgce
Pank1
Fgd3

1.53
1.52
1.52
1.52

9.38E-04
1.24E-03
6.25E-03
1.33E-03

1432362_at
1431874_at

Cenpp
1.52
4931429L15 1.51
Rik
Atad2b
1.51

1.66E-03
4.89E-03

Probeset
1434869_at
1458505_at
1429960_at
1418186_at
1451038_at
1443633_at

1446719_at

6.23E-03
7.05E-03
4.81E-03
5.55E-03
1.86E-04
4.61E-03

7.03E-03
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Gene Description
tudor domain containing 3
hypothetical LOC552901
RIKEN cDNA 4930438A08
gene
glutathione S-transferase,
theta 1
apelin
RIKEN cDNA 1700086O06
gene
Transcribed locus
Transcribed locus
Yip1 domain family, member 7
hepatocyte growth factor
expressed sequence AI661384
vesicle-associated membrane
protein 5
solute carrier family 5 (inositol
transporters), member 3
Signal-induced proliferationassociated 1 like 1
protein kinase, cAMP
dependent regulatory, type II
beta
Transcribed locus
sarcoglycan, epsilon
pantothenate kinase 1
FYVE, RhoGEF and PH
domain containing 3
centromere protein P
RIKEN cDNA 4931429L15
gene
ATPase family, AAA domain
containing 2B

Table 2-4. The 33 probesets downregulated by HOXB4-ERT2.

Probeset
1416003_at
1447683_x_at
1435529_at

Paired tFold
Test p
Chng
Value
Cldn11
-3.85 4.11E-03
Mettl1
-2.44 2.39E-03
OTTMUSG0 -2.33 8.63E-03
0000016644
Gene
Symbol

Gene Description
claudin 11
methyltransferase-like 1
predicted gene,
OTTMUSG00000016644

1417963_at
1435792_at
1420671_x_at

Pltp
Csprs
Ms4a4c

-2.27
-2.27
-2.22

1.92E-03 phospholipid transfer protein
1.90E-03 component of Sp100-rs
1.55E-03 membrane-spanning 4domains, subfamily A, member
4C

1450616_at

Ear5

-2.04

4.27E-03 eosinophil-associated,
ribonuclease A family, member
5

1443956_at
1416023_at

Zfp397
Fabp3

-2.00
-2.00

5.84E-03 zinc finger protein 397
7.63E-03 fatty acid binding protein 3,
muscle and heart

1429984_at

5730455O13 -1.96
Rik

8.95E-03 RIKEN cDNA 5730455O13
gene

1417500_a_at

Tgm2

6.51E-03 transglutaminase 2, C
polypeptide

1423963_at

LOC1000456 -1.79
29

1.60E-03 similar to myocardial ischemic
preconditioning upregulated
protein 2

1452361_at
1430388_a_at

Rnf20
Sulf2

-1.75
-1.72

2.32E-04 ring finger protein 20
2.84E-03 sulfatase 2

1437347_at
1416289_at

Ednrb
Plod1

-1.72
-1.69

9.05E-04 endothelin receptor type B
4.00E-04 procollagen-lysine, 2oxoglutarate 5-dioxygenase 1

1449195_s_at

Cxcl16

-1.67

3.40E-03 chemokine (C-X-C motif) ligand
16

-1.85
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Table 2-4. Continued.

Probeset
1421604_a_at
1428535_at
1460648_at
1424986_s_at

1425658_at
1450488_at
1417865_at
1424498_at
1454676_s_at
1446528_at
1452014_a_at
1422054_a_at
1416654_at
1426847_at

1439348_at
1416044_at

Paired tFold
Test p
Gene Description
Chng
Value
Klf3
-1.64 8.60E-04 Kruppel-like factor 3 (basic)
9430020K01 -1.64 6.12E-03 RIKEN cDNA 9430020K01
Rik
gene
Nr2f6
-1.64 8.25E-03 nuclear receptor subfamily 2,
group F, member 6
Fbxw7
-1.61 2.52E-03 F-box and WD-40 domain
protein 7, archipelago homolog
(Drosophila)
Cd109
-1.56 3.26E-03 CD109 antigen
Ccl24
-1.56 8.04E-03 chemokine (C-C motif) ligand
24
Tnfaip1
-1.54 5.89E-03 tumor necrosis factor, alphainduced protein 1 (endothelial)
5730596K20 -1.54 8.06E-03 RIKEN cDNA 5730596K20
Rik
gene
Ticam1
-1.54 9.53E-03 toll-like receptor adaptor
molecule 1
Scyl2
-1.52 8.18E-03 SCY1-like 2 (S. cerevisiae)
Igf1
-1.52 8.07E-03 insulin-like growth factor 1
Skil
-1.52 9.93E-03 SKI-like
Slc31a2
-1.52 3.57E-03 solute carrier family 31,
member 2
Sirt4
-1.52 1.38E-03 sirtuin 4 (silent mating type
information regulation 2
homolog) 4 (S. cerevisiae)
S100a10
-1.52 7.14E-03 S100 calcium binding protein
A10 (calpactin)
Flii
-1.52 1.40E-03 flightless I homolog
(Drosophila)
Gene
Symbol
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Figure 2-7. Hierarchical cluster diagram and heat map of the 77 candidate
probesets selected from 4 biologically-independent experiments using the
log2-ratio of TAM-induced HOXB4-ERT2 vs. TAM-induced GFP expression
values observed within each of the 4 experiments.
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Figure 2-8. Hierarchical cluster diagram and heat map of the 77 candidate
probesets selected from 4 biologically-independent experiments using the
normalized z-score.
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Figure 2-9. Functional classification of the 77 probesets by using gene
ontology annotations. Some probesets were classified into more than one
category, thus the sum of all 11 groups is more than 77.
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Figure 2-10. Quantitative real-time PCR confirmation of the expression
change of the selected 8 candidate target genes from independent
experiments with TAM treatment for 6 hours or 12 hours in HOXB4-ERT2
vector-transduced and GFP control vector-transduced Lin- bone marrow
cells.
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∆∆CT method was used for quantification of relative gene expression levels.
The housekeeping gene Gapdh was used as an internal control for gene
expression normalization. The plot of template cDNA dilution vs. ∆CT was close
to zero, verifying the approximately equal PCR amplification effiencies of the
tested genes and the endogenous Gapdh control. Then the CT values of the
tested target gene and Gapdh control in HOXB4-ERT2 sample were compared to
the CT values of them in the GFP sample to generate a relative expression
change of this specific target gene between the 2 samples.
The quantitative PCR results correlated fairly well with the microarray data and
also showed that changes in the gene expression present in 12 hours TAMtreated samples were also present at 6 hours after TAM treatment, consistent
with an immediate transcriptional effect.
2.4.6 Hemgn mRNA Expression Level in Bone Marrow and c-kit+Scal-1+LinCells from Hoxb4-/- Mice
Hemgn was one most interesting gene that was upregulated at a relatively
high level compared to other genes and appeared to be an interesting gene for
further study. Hemgn is a nuclear protein specifically expressed in hematopoietic
stem and progenitor cells that appears to protect cells from apoptosis and
differentiation.170;172 We obtained whole bone marrow and c-kit+scal-1+Lin- bone
marrow cells from Hoxb4-/- mice and showed by real-time PCR that Hemgn
mRNA was significantly decreased relative to that seen in control cells from wild
type mice (Figure 2-11), indicating that Hemgn may also be regulated by
endogenous Hoxb4. The ∆∆CT method was used for quantification of the relative
gene expression level.
2.5 Discussion
The function of transcription factors may be confounded by factors such as
redundancy, pleiotropic overlap, sequential downstream pathway activation due
to the ectopic expression. The use of inducible expression cassettes or inducible
nuclear targeting of transcription factors may overcome these limitations, and
such systems have been widely used for direct target identification of
transcription factors. In our study, an inducible HOXB4-ERT2 system was
generated and proved to work well in vitro, recapitulating the functional
phenotype caused by HOXB4 overexpression. Most importantly, the inducible
construct did not cause any detectable leakiness in the absence of TAM
treatment. Our use of the inducible HOXB4-ERT2 system allowed the
identification of very early and potential direct downstream effectors of HOXB4,
with the controlled application of TAM. A significant advantage of this system is
that it ensures the detected gene expression changes are based on biological
coherence instead of random events, since the myeloid progenitor CFU-C
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Figure 2-11. Quantitative real-time PCR detection of relative expression
level of Hemgn mRNA in whole bone marrow or c-kit+Scal-1+Lin- (KSL) cells
from Hoxb4-/- mice compared to wild type (WT) mice. The calculation is based
on the quantitative comparative CT (2-∆∆CT) method with normalization to Actb
internal control. Four biological independent experiments were applied in this
assay.
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assays were validated in advance to reflect the function of induced HOXB4 in
promoting hematopoietic progenitor cell expansion.
The gene profiling assay for the expression change between the HOXB4-ERT2
plus TAM samples versus the GFP plus TAM samples is a reasonable
comparison method to exclude the effect caused by TAM itself. The criteria for
screening the targets of HOXB4 were stringent in our study. A 1.5 fold threshold
for gene differential change was selected since only 60 to 70% of the cells in a
given sample were transduced, hence the 1.5 fold change measured from the
samples would underestimate what actually occurred in the transduced cells. I
tried once to sort transduced bone marrow cells for the gene screening assay,
but due to the variance generated from the sorting process to the cells, I decided
to use non-sorted cells in this study. We found HOXB4 activation did not induce a
global gene expression change, as the gene expression showed high
reproducibility between and within each experiment, indicated by the fact that the
pearson correlation coefficients between the 8 experimental samples ranged
from 0.91 to 0.97. This data indicate that the chromatin structure was not altered
to initiate a global change in gene expression, and only a small subset of specific
genes were impacted by HOXB4 activation. Hierarchical clustering analysis and
heat map generated from the identified 77 probesets from the 4 independent
experiments further validated the high reproducibility between experiments. In
this small target gene list, we found that 44 genes were reproducibly upregulated
and 33 of them were downregulated by HOXB4, indicating that HOXB4 can both
activate and repress downstream gene expression, which is consistent with
previous results.140 The identified target genes were shown to be involved in a
variety of cellular processes, of which, the ones classified in signaling pathways,
development and differentiation, cell proliferation and growth might be the most
significant targets for further focus.
Further PCR confirmation of the selected genes with highest fold change
between HOXB4-ERT2 and GFP samples validated the quality of the data
generated from microarray screening. As 12 hours TAM treatment was used in
microarray assays, to discern whether the detected gene expression change also
exists at an earlier time point, samples from 6 hours of TAM treatment were also
included and showed that most of the studied genes were also altered at 6 hours.
A gene called Hemgn was pursued further based on its relative high degree of
expression change. After reviewing the literature, we found that relatively little is
known about Hemgn, which was cloned in 2001.170 Its expression is restricted to
testis and hematopoietic tissues. In this regard, its spatial and temporal
expression pattern is similar to endogenous Hoxb4. Overexpression of human
HEMGN in transgenic mice caused disruption of the balance of myelopoiesis
and lymphopoiesis,173 suggesting an important role in hematopoiesis. This
promoted us to study Hemgn further as an important HOXB4 target gene.
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We recognize that other potential HOXB4 target genes identified from
microarray screening are also likely to contribute to the downstream signaling
network of HOXB4 in conveying its function. This 77 candidate list can serve as a
resource for further research on HOXB4-promoted expansion effect. We did
select several genes with relative high degrees of changes in expression
between HOXB4-ERT2 and GFP samples based on microarray and real-time
PCR results. I cloned their cDNA upstream of the IRES cassette in the MSCVIRES-GFP retroviral vector for overexpression study. Stable GPE+86 vector
producer cell lines overexpressing those individual target genes were generated
to provide vector supernatant for bone marrow transduction. Bone marrow cells
overexpressing individual target genes were tested for myeloid progenitor
expansion ability in the secondary CFU-C assay as a prompt in vitro evaluation
method for their function. In this assay, however, only Hemgn showed ability to
promote myeloid progenitor expansion in vitro. Two of the upregulated genes by
HOXB4: Thy1 or Ephx2, when overexpressed, did not cause expansion of
myeloid progenitor cells. In contrast, one of the downregulated genes by HOXB4:
Ms4a4c, inhibited expansion of myeloid progenitor cells when it was
overexpressed. This suggests that downregulation of Ms4a4c could be a
mechanism of HOXB4’s expansion ability. In general, the data provided us an
additional practical reason to focus on investigating Hemgn instead of other
candidates in our study.
Interestingly, the mRNA expression of Hemgn also showed correlation with
endogenous Hoxb4 expression. A 5-fold decrease in Hemgn mRNA was found in
Hoxb4-deficient c-kit+Scal-1+Lin- bone marrow cells compared to wild type cells.
This data further strengthens the hypothesis that Hemgn is regulated by HOXB4.
Because the expression of Hemgn can still be detected in the absence of Hoxb4,
the residual amount of Hemgn expression possibly still effectively maintains the
normal hematopoietic stem and progenitor cell expansion. Since Hox4 paralog
members show redundancy in their functions,167 investigation of whether Hemgn
could be further downregulated in Hoxa4;b4;c4;d4 quadruplex knockout mice
would be interesting.
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CHAPTER 3. DEMONSTRATION THAT HEMGN IS A DIRECT
TRANSCRIPTIONAL TARGET OF HOXB4
3.1 Summary
Among the 77 candidate target genes identified by microarray screening using
the HOXB4-ERT2 inducible system, Hemogen (Hemgn), a newly discovered
nuclear protein specifically expressed in hematopoietic cells with reported
functions in blocking apoptosis, inhibiting differentiation, and promoting survival,
is a particularly interesting one for us to pursue further. Here we show that
Hemgn is indeed the first identified direct transcriptional target of HOXB4 in
primary bone marrow cells. Promoter activity of Hemgn was increased by
HOXB4 in MEL cells in transient co-activation assays, implying direct
transactivation of Hemgn by HOXB4. Furthermore, we show HOXB4 directly
bound to the promoter fragment of Hemgn in electrophoresis mobility shift assay
(EMSA). Most importantly, we validated that HOXB4 was recruited in vivo to the
Hemgn promoter region in primary 5-FU treated hematopoietic progenitor cellenriched bone marrow cells, through chromatin immunoprecipitation (ChIP)
assay.
3.2 Introduction
Traditionally, experimental approaches have sought to identify target genes of
transcription factors by measuring gene expression in loss- or gain-of-function
assays, while transcription factor-binding to transcriptional regulatory regions has
been evaluated using EMSA, co-transfection or ChIP assays. Classic microarray
for gene expression profiling or genome-wide location data for transcription factor
binding from ChIP-chip experiments does not provide definitive evidence of
target regulation. These screening methods should always be combined with
functional biological experiments for targets confirmation.
Among the potential candidates from the microarray screening, we decided to
focus on Hemgn, based on its relatively high degree of upregulated expression
induced by HOXB4, its known hematopoietic expression pattern, and given the
fact that relatively little is known about this gene and its potential function in
hematopoiesis. Hemgn is a recently discovered nuclear protein that is
restrictively expressed in testis and hematopoietic tissues.170;171 It shows a
spatial and temporal expression pattern in hematopoietic sites during
embryogenesis, and is expressed in the blood islands of yolk sac, then in fetal
liver, and finally in the adult spleen and bone marrow.170 In adult bone marrow,
Hemgn is predominantly expressed in primitive progenitor and stem cell
populations, but not in terminally differentiated mature blood cells.170 Human
HEMGN, also called EDAG, shows a similar expression pattern in bone marrow
cells and interestingly, maps to chromosome 9q22 which contains well known
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leukemic breakpoints.170 Relatively high levels of EDAG expression have been
observed in human acute myeloid leukemia bone marrow cells.175 In transgenic
mice in which EDAG was driven by human CD11a promoter, enhancement of
myelopoiesis and suppression of lymphopoiesis was found, suggesting its
regulatory role in hematopoiesis.173 To our knowledge, Hemgn has not been
knocked out in a mouse genetic model so that the null phenotype is unknown.
The activity of the Hemgn promoter containing 2975 bp of 5' flanking sequence
and 196 bp of 5' UTR was tested in a luciferase assay and was reported to be
active in a hematopoietic cell line K562, but not in nonhematopoietic cell lines.184
This promoter region was also able to drive the transcription of a lacZ transgene
in hematopoietic tissues in transgenic mice.184 GATA1 was demonstrated to bind
to 2 GATA binding sites in this promoter region of Hemgn in the K562 cells and
to transactivate it. EMSA showed direct binding of GATA1 to the Hemgn
promoter in MEL cells. ChIP assay showed the recruitment of GATA1 to Hemgn
promoter in Meg-01 AML cell line. This study suggests that the Hemgn promoter
contains critical regulatory elements for its transcription in hematopoietic tissues
and Hemgn is a direct target of GATA1 in leukemia cell line K562.184 Except for
the data from this report, there is no other literature on the transcriptional
regulation of Hemgn and no information exists for its regulation in primary
hematopoietic cells.
In this study, after using the traditional method for identifying the target genes
in a gain-of-function model of HOXB4, we then focused on validating a specific
target, Hemgn, with supplemental co-transfection, EMSA, and ChIP assays.
3.3 Materials and Methods
3.3.1 Transient Cotransfection Luciferase Assay
In the promoter region of Hemgn, -1887bp ~ +213bp region containing the 4
putative HOXB4 binding sites based on sequence analysis. The transcription
start site (TSS) was cloned upstream of a luciferase reporter gene in pGL4.12Luc2CP vector (Promega, Madison, WI). 1 µg pGL4.12-Luc2CP vector and 0.5
ng renilla control pGL4.75-Rluc/CMV vector were transiently transfected with
either 1 µg MSCV-IRES-GFP control or 1 µg MSCV-HOXB4-IRES-GFP vector
into 2X105 MEL cells with 4 µl Fugene 6 reagent (Roche Applied Science,
Indianapolis, IN). Luciferase activity was measured by dual-luciferase reporter
assay system (Promega, Madison, WI) 48 hours after transfection and was
normalized to renilla activity.
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3.3.2 Electrophoretic Mobility Shift Assay (EMSA)
A GST-tag was fused to the N-terminus of HOXB4 protein and the GSTHOXB4 fusion protein was expressed and purified through pET-GST Fusion
System 42 (Novagen, EMD Chemicals Inc, San Diego, CA). Synthetic single
strand DNA oligos were biotin-labeled with Biotin 3’ END DNA labeling kit
(Pierce, Holmdel, NJ) and annealed. The reactions were processed using
LightShift Chemiluminescent EMSA Kit (Pierce, Holmdel, NJ) according to the
manufacturer’s instructions. Briefly, 20 fmol biotin-labeled probes were incubated
with 5 µg GST or GST-HOXB4 protein, together with 2 µl 10x binding buffer, 1 µg
poly(dI.dC), HBC loading buffer (20% Glycerol, 20 mM HEPES (PH7.8), 0.2 mM
EDTA, 1 mM DTT) and ultrapure water to a final 20 µl reaction volumn. For the
cold probe competition reactions, 4 pmol unlabelled target oligos were
additionally added in the reactions. For supershift analysis, 1 µg Anti-HOXB4
antibody (clone I12) (The Developmental Studies Hybridoma Bank, the University
of Iowa, Iowa City, IA) was incubated with 5 µg GST or GST-HOXB4 for 30
minutes on ice preceding the DNA binding reaction. The DNA-protein complexes
were separated by 6% TBE DNA retardation gel (Invitrogen, Carlsbad, California)
and transferred to Biodyne B Nylon Membrane (Pierce, Rockford, IL). The probe
containing complex in the crosslinked membrane was recognized by streptavidinHRP and incubated with the substrate. The luminescent signal was captured by
X-ray film. The sequence of the WT probe for the promoter of Hemgn is:
5’ ACACTCTGCTAATTACAGCCTTT 3’ (-1562bp ~ -1540bp); and sequence of
the mutant probe is: 5’ ACACTCTGCAGCATACAGCCTTT 3’.
3.3.3 Separation and Transduction of 5-FU Treated Bone Marrow Cells
Bone marrow cells were harvested 4 days after intraperitoneal injection of mice
with 150 mg/kg 5-FU185;186 from the tibias and femurs of 7 to 12 weeks old female
C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) as previously
described.182 Red blood cells were lysed with BD pharm LyseTM lysing buffer (BD
Biosciences, San Jose, CA). The 5-FU treated bone marrow cells were
prestimulated for 2 days with the cytokine-supplemented DMEM medium
described in Chapter 2. The method for transduction of the cells with retroviral
vector supernatant collected from the GPE+86 producer cells were described in
Chapter 2. After transduction, cells were collected for ChIP assay.
3.3.4 Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed using ChIP-IT™ Express kit (Active Motif,
Carlsbad, CA) following the manufacturer’s instructions. Briefly, the transduced
5-FU treated bone marrow cells were fixed with 1% formaldehyde for 10 minutes
at room temperature, and the chromatin from 2x107 cells was sonicated into
fragments (~500bp). The chromatin-protein complex derived from 2.5x106 cells
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was immunoprecipitated with either 1 µg anti-HOXB4 antibody (I12) or 1 µg
IgG2A isotype control antibody (R&D Systems, Minneapolis, MN). The semiquantitative PCR (Tag PCR core kit, Qiagen, Valencia, CA) was set as follow:
94ºC 5 minutes; 35 cycles alternating between 94ºC for 1 minute, 60ºC for 1
minute and 72ºC for 1 minute; 72ºC 10 minutes. The quantitative real-time PCR
was performed with SYBR Green DNA incorporation method by using
QuantiTect TM SBBR Green PCR kit (Qiagen) and was carried out on
StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA),
and was analyzed with quantitative comparative CT (2-∆∆CT) method normalized to
input control samples using StepOne Software v2.0 (Applied Biosystem, Foster
City, CA). The PCR reaction program was set up as follow: 95°C 10 min; 40
cycles alternating between 95°C 15 seconds and 60°C 1 minute. The melting
curves were generated by the program to validate one single PCR product for
each reaction. The results were analyzed in quantitative comparative CT (2-∆∆CT)
method normalized to input control samples using StepOne Software v2.0
(Applied Biosystem, Foster City, CA).
The PCR primers are listed below:
1. Semi-quantitative and quantitative real time PCR primers for amplifying -54bp
~ +89bp in the promoter of Actb:
Forward: 5’ CGCGAGCACAGCTTCTTTG 3’
Reverse: 5’ GGTGTCCGTTCTGAGTGATCC 3’
2. Semi-quantitative PCR primers for amplifying regions in Hemgn promoter:
(1). -1568bp ~ -1447bp region:
Forward: 5’ GCCACCACACTCTGCTAATTAC 3’
Reverse: 5’ CGGAGAGGAAACTAGGAAAG 3’
(Also used in quantitative real time PCR)
(2). -543bp ~ -228 bp region:
Forward: 5’ GGTGAGCAGTGGAGATTAGC 3’
Reverse: 5’ AGGGAGATCCCAGGGTTTAG 3’
3. Quantitative real-time PCR primers for amplifying regions in Hemgn promoter:
(1). -1731bp ~ -1542bp region
Forward: 5’ AGGATGGTGAGTTGAGGTCGGC 3’
Reverse: 5’ AGGCTGTAATTAGCAGAGTGTGGTGG 3’
(2). -1485bp ~ -1336bp region
Forward: 5’ ACATTTCAAATGCTAGCCCCTTTCC 3’
Reverse: 5’ CACCTTCTCTCTCTTTATGCACACATGT 3’
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(3). -436bp ~ -332bp region
Forward: 5’ GTGAAAACATAGCCACACCTAGGAAGAT 3’
Reverse: 5’ CCACTCTTGCCTGTTTCATACACTTCTT 3’
3.4 Results
3.4.1 The Promoter of Hemgn Contains Potential HOXB4 Binding Motifs
Inspection of the promoter region (-1887bp ~ +213bp) of Hemgn revealed 4
potential HOXB4 binding sites with a “TAAT” core and preferred flanking
nucleotides (Figure 3-1). We know that the “TAAT” core sequence is relatively
common and could appear in any potential cis-regulatory elements, which could
be in the promoter region 5’ to Hemgn, or in an intron, or in the 3’ untranslated
region of Hemgn. Here we only examined the ~2 kb promoter region of Hemgn,
and all the following functional evaluation were based on this region. The
existence of multiple “TAAT” sites in this ~2 kb fragment suggests a potential
increased abundance of HOXB4 on this promoter region due to the widespread
binding sites. The specificity of potential HOXB4 binding is possible based on
preferred flanking nucleotides of the 4 “TAAT”.
3.4.2 The Promoter of Hemgn Was Transcriptionally Activated by HOXB4
The -1887bp ~ +213bp region containing the 4 potential HOXB4 sites and the
transcription start site (TSS) was cloned upstream of a luciferase reporter gene
and this construct was tested in a transient transfection assay in mouse
erythroleukemia (MEL) cells. When this construct was co-transfected with an
internal renilla control vector and an MSCV vector expressing either HOXB4 or a
GFP control protein, HOXB4 significantly increased the luciferase activity in MEL
cells (Figure 3-2), indicating that the promoter of Hemgn was directly activated by
HOXB4. However, the limitation of this assay is that first, the Hemgn promoter
fragment used in the transfected luciferase reporter plasmid may not mimic the
true transcriptional regulation of the endogenous gene. Second, both plasmid
DNA and HOXB4 protein expression are introduced transiently and at high
episomal copy numbers; far beyond the physiological level, potentially forcing
non-physiologic the DNA-protein interactions. Third, a cell line instead of primary
cells in this assay based on transfection efficiency considerations. Therefore, we
sought independent confirmation of this putative interaction.
3.4.3 HOXB4 Directly Bound to the Promoter Fragment of Hemgn In Vitro
Among the 4 putative HOXB4 binding sites (Figure 3-1), site 1 (-1555bp~1548bp) contains the most favored flanking nucleotides for high affinity HOXB4
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Figure 3-1. Schematic illustration of the multiple putative HOXB4 binding
sites on the promoter region of Hemgn (site 1, 2, 3 and 4).

Figure 3-2. HOXB4-dependent increase in promoter activity of Hemgn in
MEL cells. * p<0.05
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binding.129 To directly test whether HOXB4 can bind to this site, we designed
DNA oligonucleotide probes spanning this specific site (-1562bp ~ -1540bp) to
examine the binding of HOXB4 by using EMSA. Indeed, HOXB4 binding caused
a band shift that was detected when the biotin-labeled wild type (WT) probe was
incubated with purified GST-HOXB4 protein (Figure 3-3, lane 2). No band
shiftwas detected in the reactions with a competitive unlabeled probe (lane 4), or
a probe containing mutated “TAAT” core sequence (lane 6), or with control GST
protein (lane 1, 3, 5, and 7). Addition of a HOXB4 antibody resulted in
supershifting of the specifically retarded fragment (lane 8). These results
demonstrate that HOXB4 can directly bind to site 1 in the promoter region of
Hemgn in vitro. The limitation of this assay lies in the fact that excessive probes
and purified HOXB4 protein were incubated together in vitro in reaction tube, and
therefore do not directly test for in vivo occupancy of sites.
3.4.4 HOXB4 Was Recruited to the Promoter Region of Hemgn In Vivo
To discern whether HOXB4 can be recruited to the promoter region of Hemgn
in bone marrow cells in vivo, we developed the first reported ChIP assay for
HOXB4 binding in transduced bone marrow cells by using an anti-HOXB4
antibody (clone I12) that we first showed can be used to efficiently
immunoprecipitate HOXB4 from a HOXB4-overexpressing cell line (Figure 3-4).
The advantage of the ChIP assay is that the detected DNA-protein interaction
occurs in the living cells in vivo instead of in artificial established in vitro system,
faithfully reflecting the true biological process in a physiological
microenvironment. Primary bone marrow cells were used here in which enforced
expression of HOXB4 was shown to induce expansion of myeloid progenitor cells.
PCR primers were designed to span several regions in the cis-regulatory
elements of Hemgn that cantain each of the four putative HOXB4 binding sites.
Cellular extracts from transduced bone marrow cells were immunoprecipitated
with the I12 antibody and DNA fragments of an average 500bp in size were
released for PCR detection (Figure 3-5). We designed semi-quantitative PCR
primer pairs to span the -1568bp ~ -1447bp region containing 2 putative HOXB4
binding sites (site 1 and site 2, Figure 3-1) or to span the -543bp ~ -228bp region
which contains 1 putative site (site 4, Figure 3-1). These two regions were
specifically enriched by the I12 anti-HOXB4 antibody in the HOXB4-transduced
bone marrow cells (Figure 3-6). In contrast, neither of these two regions was
enriched in cells transduced with the GFP control vector, or in HOXB4 vectortransduced cells immunoprecipitated using an isotype control antibody. PCR
primers amplifying an irrelevant region in Actb promoter containing no “TAAT”
sequence showed no detectable enrichment with either antibody (Figure 3-6).
These results verify that HOXB4 bound to the promoter of Hemgn in vivo in
primary bone marrow cells that overexpressed HOXB4.
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Figure 3-3. HOXB4-specific binding caused band shift of probes containing
the putative HOXB4 binding site (site 1) in EMSA. 1-2: biotin-labeled WT
probe (-1562~-1540bp of Hemgn promoter); 3-4: labeled WT probe: competitive
unlabeled probe=1:200; 5-6: probe with “TAAT” core sequence mutated to
“AGCA”; 7-8: labeled WT probe + anti HOXB4 antibody (I12); solid arrow: band
shift by HOXB4; open arrow: supershift by I12; #: degraded GST-HOXB4 caused
band shift.
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Figure 3-4. Immunoprecipitation and western blotting detection of HOXB4
protein from GPE+86 cells overexpressed with GFP control or HOXB4 with
monoclonal anti-HOXB4 antibody (I12).
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Figure 3-5. Sonicated chromatin fragments from GFP or HOXB4-transduced
bone marrow cells for ChIP assay.
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Figure 3-6. Semi-quantitative PCR detected enrichment of the promoter
fragments of Hemgn by HOXB4 specific binding following ChIP assay in
transduced bone marrow cells.
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To further quantify the fold enrichment of HOXB4 on the individual “TAAT” site,
quantitative real-time PCR primers were designed to amplify the individual
putative HOXB4 binding site in a 5’ to 3’ order in the promoter of Hemgn (Figure
3-7). The -1731bp~-1542bp (site 1, Figure 3-1) and the -436bp~-332bp (site 4,
Figure 3-1) regions were enriched at relatively higher levels (16.1 fold and 34.8
fold). As sites 1, 2 and 3 are very close to each other within 500bp, and due to
the sonicated chromatin being around 500bp, probably all the 4 sites contributed
to direct binding by HOXB4.
3.5 Discussion
Classic microarray analysis for gene expression profiling does not provide
definitive evidence of target gene relationships and needs to be combined with
DNA binding data in order to identify direct target genes. In our study, the binding
of the HOXB4 transcription factor to a target promoter has been measured using
transient co-activation assays, EMSA, and ChIP assays. We selected a specific
candidate target gene, called Hemgn, for these studies for the reasons discussed
in Chapter 2, but this could in principle be done with any of the genes in our list.
Multiple “TAAT” core sequences with HOXB4-preferred flanking nucleotides
were found within the 2kb promoter region of Hemgn. As mentioned previously in
Chapter 1, Hox regulation of downstream target genes occurs through binding to
specific conserved DNA sequences in their regulatory elements. However, other
Hox family members in addition to HOXB4 may also bind to the same “TAAT”
core sequence through the homeodomain. Discrepancy exists between the
relatively promiscuous binding of Hox monomers to DNA and the high specificity
of Hox protein functions. It is hypothesized that the specificity of the downstream
target regulation of Hox strongly depends on the flanking nucleotides surrounding
the core sequence and on the cofactors which interact with Hox proteins to
further increase the selective binding of Hox and cofactor heterdimers to DNA.
However, prior studies have shown that one cofactor of HOXB4, Pbx, is not
required, and even limits, HOXB4-induced expansion of hematopoietic stem and
progenitor cells in vitro and in vivo.140;168;169 Thus, the binding specificity of
HOXB4 to regulatory elements in its target genes are more likely dependent on
the flanking DNA sequence surrounding the “TAAT” core. The binding affinity
possibly could be enhanced with existence of multiple “TAAT” core sequence
other than single one in the regulatory elements.
We proved that at least some of the “TAAT” containing promoter sequences of
Hemgn can be transcriptionally activated by HOXB4 in vitro by luciferase reporter
assays, implying that this promoter is regulated by HOXB4 in vivo. Furthermore,
direct binding of purified HOXB4 to a promoter fragment of Hemgn was
confirmed in vitro by EMSA. This finding suggests that the protein-DNA complex
can be formed with purified GST-HOXB4 and that other cofactors of HOXB4
such as Pbx are not required for the direct binding of HOXB4 to these sequences.
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Figure 3-7. Quantitative real-time PCR detected relative enrichment of
individual regions in Hemgn promoter by HOXB4 following ChIP assay in
transduced bone marrow cells. All values were normalized to the
corresponding input control sample.
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For the first time, we have established a ChIP assay for HOXB4 binding and
show that Hemgn is indeed a direct target gene of HOXB4 in vivo. This validated
in vivo HOXB4 binding region encompasses multiple “TAAT” sites identified in
the promoter region of Hemgn. Intriguingly, each of the four “TAAT” sites in the
promoter region of Hemgn was enriched to a similar extent in
immunoprecipitated samples. This is possibly due to the fact that those “TAAT”
sites are close in location, thus multiple “TAAT” sites within the 500bp sonicated
chromatin fragments were immunoprecipitated and detected by PCR. It is
necessary to mention again that when we mutated the “TAAT” core on site 1
which contains the most favored flanking nucleotides of HOXB4, the
GST-HOXB4-DNA interaction was disrupted in vitro in EMSA. However, to
determine exactly which site contributes most to the binding and downstream
functional effects, site-mutagenesis assays could be performed in future studies.
In ChIP assays, we used constitutively overexpressed HOXB4 instead of
inducible HOXB4-ERT2, based on the fact that although Hemgn is upregulated by
HOXB4-ERT2 as early as 6 hours after TAM treatment, expression of Hemgn is
also maintained at a high level in constitutively overexpressed HOXB4 samples
by microarray (Brian P. Sorrentino’s lab, data not shown). These data indicate
that the direct regulation of Hemgn by HOXB4 is persistent after the initial binding
and activation.
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CHAPTER 4. EXPRESSION OF HEMGN EXPANDS BONE
MARROW AND HEMATOPOIETIC PROGENITOR CELLS AND
PROTECTS AGAINST APOPTOSIS
4.1 Summary
To discern whether Hemgn is a downstream functional target of HOXB4, we
constructed a MSCV retroviral vector for Hemgn overexpression. When
overexpressed in 5-FU treated bone marrow cells, Hemgn promoted expansion
of bone marrow cells and myeloid progenitor cells in in vitro liquid cultures and in
secondary colony forming unit-culture (CFU-C) assays, recapitulating the effect
of overexpressed HOXB4. Furthermore, both Hemgn and HOXB4 were
antiapoptotic in transduced 5-FU treated bone marrow cells following cytokine
withdrawal, suggesting a possible cellular mechanism for understanding the role
of Hemgn in promoting expansion of primitive hematopoietic cells.
4.2 Introduction
Hemgn is a recently discovered nuclear protein that is expressed in testis and
hematopoietic tissues.170;171 In bone marrow, Hemgn is predominantly expressed
in primitive progenitor and stem cell populations, but not in terminal differentiated
mature blood cells.170 In transgenic mice in which EDAG, the human homolog of
Hemgn, was driven by human CD11a promoter, enhancement of myelopoiesis
and suppression of lymphopoiesis was found, suggesting a regulatory role in
hematopoiesis.173 Since HOXB4 overexpression can cause bone marrow cell
expansion during extended culture with myeloid cytokines,95 and because
Hemgn is a direct transcriptional target of HOXB4 as discussed in Chapter 3, it is
necessary to study the functional effects of Hemgn and whether Hemgn
overexpression could recapitulate the expansion phenotype of HOXB4.
4.3 Materials and Methods
4.3.1 Vector Construction
The murine Hemgn cDNA (NCBI Reference Sequence: NM_053149.2) was
cloned into XhoI sites in MSCV-IRES-GFP backbone including the following
sequences from the 5’ UTR:
5’ AAGCTTTTAGGCTGCTTGTGAAGTCAAAGCCAATACCAAGAAGGCATCGT
GGCAAG 3’ and the 3’ UTR: 5’ CAGTGCTCAGT 3’ (Figure 4-1). A polyclonal
population of ecotropic retroviral producer GPE+86 cells179 was generated using
a previously described approach.180;181 Briefly, 2 µg pCAGGS-VSVG and 4 µg
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Figure 4-1. Hemgn-expressing retroviral vector. (A) MSCV-retroviral vector
construct with cDNA of Hemgn inserted upstream IRES cassette. (B) DNA
sequence of the cloned 5’UTR together with 3’UTR of the cDNA of Hemgn in the
MSCV vector.
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pEQ-PAM3(-E) helper plasmids were co-transfected with 4 µg MSCV-cDNAIRES-GFP vector into 8x106 cycling 293T cells using FuGENE 6 reagent (Roche
applied Science, Indianapolis, IN) according to the manufacturer’s instructions.
Retroviral vector supernatant were harvested 48 hours post transfection, pooled,
filtered through 0.45 µm PVDF filter (Millipore, Billerica, MA), and used for
transducing the cycling GPE+86 cells in the present of 6 µg/ml polybrene. The
transduced GFP positive GPE+86 cells were sorted and expanded in culture for
establishing stable retroviral vector producer lines. The helper-free recombinant
retroviral vector supernatants freshly collected from the GPE+86 producer cells
were filtered through 0.45 µm pore filter for transduction of bone marrow cells.
4.3.2 Southern Blotting
GPE+86 retroviral vector producer cells transduced with MSCV-IRES-GFP,
MSCV-HOXB4-IRES-GFP, or MSCV-Hemgn-IRES-GFP vector were used in
these assays. The genomic DNA extracted from the cells was digested with SacI
to release the cDNA-IRES-GFP fragment between the 2 LTRs of the
MSCV-cDNA-IRES-GFP vectors. A probe targeting GFP was used for detecting
the liberated fragment.
4.3.3 Western Blotting
Whole cell extracts were prepared from GPE+86 cells by M-PER Mammalian
protein extraction reagent (Pierce, Thermo Scientific, Rockford, IL) supplemented
with the protease inhibitors (HaltTM protease inhibitor cocktail kit, Thromo
Scientific, Rockford, IL; Pefabloc SC Plus, Roche Applied Science, Indianapolis,
IN). The proteins were then resolved on a 4-12% gradient NuPAGE Bis-Tris gel
(Invitrogen) and transferred to 0.45 μm PVDF membranes. The primary rabbit
polyclonal IgG antibody for detecting Hemgn of mouse origin (M-180, sc-68360,
Santa Cruz Biotechnology, INC, Santa Cruz, CA) was used for Hemgn detection.
4.3.4 Transduction of 5-FU Treated Bone Marrow Cells
The 5-FU treated bone marrow cells were prepared as described in Chapter 3.
Briefly, bone marrow cells were harvested 4 days after intraperitoneal injection of
mice with 150 mg/kg 5-fluorouracil (5-FU)185;186 from the tibias and femurs of 7 to
12 weeks old female C57BL and6J mice (The Jackson Laboratory) as previously
described.182 Red blood cells were lysed with BD pharm LyseTM lysing buffer (BD
Biosciences, San Jose, CA). The 5-FU treated bone marrow cells were
prestimulated for 2 days with the cytokine-supplemented DMEM medium as
described in previous Chapters. The cells were then spin-infected at 2000 rpm
for 30 minutes at room temperature by using plates preloaded with 25 µg/ml
RetroNectin (Takara, Madison, WI) and retroviral vector supernatant generated
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as described above at an multiplicity of infection (MOI) of 10 to 20. After 3 to 4
rounds of transduction in 2 consecutive days, cells were collected, washed with
PBS, and then resuspended in the cytokine-supplemented medium. Proportions
of the transduced GFP positive cells were determined by flow cytometry.
4.3.5

In Vitro Expansion Assays

After retroviral vector transduction, the transduction efficiencies obtained were
typically 30% for the GFP control and HOXB4 vectors, but around 13% for the
Hemgn vector. For liquid culture and CFU-C assays, cells were mixed with nontransduced cells to have the same GFP percentage (13%), and then equal
numbers of normalized cells were cultured in cytokine-supplemented medium or
M3434 methylcellulose medium as described previously. GFP percentage was
determined by flow cytometry during the culture for evaluating growth advantage.
4.3.6 Apoptosis and Cell Cycle Assays
The transduced 5-FU treated bone marrow cells were cultured in the cytokinesupplemented Dulbecco's modified Eagle medium (DMEM) containing 20 ng/ml
recombinant mouse IL-3, 50 ng/ml human IL-6, 50 ng/ml mouse SCF (R&D
Systems, Minneapolis, MN), 15% FBS, 100 units/ml penicillin, 100 µg/ml
streptomycin and 2 mM L-glutamine (R&D Systems, Minneapolis, MN). After 6
days, cells were washed with PBS and cultured in the medium containing 1%
FBS and no cytokines. Sixteen hours later, 3x105 cells were stained with Annexin
V-allophycocyanin (APC) (BD Biosciences, Franklin Lakes, NJ). Flow cytometry
was used to detect GFP and APC percentage. For cell cycle analysis, the
transduced cells were cultured for 6 and 16 days in the cytokine-supplemented
medium and then were sorted to separate GFP positive and negative population,
which were respectively stained with PI for DNA content analysis. The ModFit
program (Verity Software House, Topsham, MI) was used to determine the
percentage of cells at the G1, S, and G2-M phases of the cell cycle.
4.4 Results
4.4.1 Expression of Hemgn in Transduced Cells
In order to answer the question whether overexpression of Hemgn could
contribute to the expansion phenotype of HOXB4, a full length cDNA of murine
Hemgn ordered from ATCC was cloned into the MSCV-IRES-GFP retroviral
vector. Integration and protein expression of Hemgn were confirmed in GPE+86
vector producer cells by southern and western blotting (Figure 4-2A and B).
However, the GFP expression from the MSCV-Hemgn-IRES-GFP vector was
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Figure 4-2. Integration, and protein expression of Hemgn and its GFP
reporter in GPE+86 vector producer and bone marrow cells. (A) Southern
blot detected the expected fragment size of integrated MSCV-cDNA-IRES-GFP
vector: Hemgn vector-4547bp; HOXB4 vector-3576bp; GFP-only vector-2881bp.
Enzyme: SacI; Probe: GFP. (B) Western blot with polyclonal anti-Hemgn
antibody (M-180) for Hemgn protein detection in GFP-only or Hemgn vectortransduced GPE+86 cells. (C) FACS analysis plot for GFP signal in bone marrow
cells transduced with GFP control, Hemgn or HOXB4 vector. (D) Western blot
detected GFP protein expression in GFP-only or Hemgn vector-transduced
GPE+86 cells. Smear bands around 50kd and 35kd: degraded Hemgn.
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relatively low compared to control vectors as indicated by the mean fluorescence
intensity for GFP signal in the transduced bone marrow cells (Figure 4-2C) and
by the western blotting for GFP in the GPE+86 vector producer cells (Figure
4-2D). Furthermore, the titer of the MSCV-Hemgn-IRES-GFP vector was
relatively low (~1x105 virus/ml compared to ~1x106 virus/ml from HOXB4
producer cells). These problems with the Hemgn vector might be due to
instability of the vector coded mRNA or the complex structure of the inserted
cDNA of Hemgn. This deficiency resulted in relatively low transduction efficiency
when bone marrow cells were transduced with this vector supernatant.
4.4.2 Hemgn Promoted Hematopoietic Cell Expansion in Liquid Culture
Despite the problems with the MSCV-Hemgn-IRES-GFP vector, I next tested
the effects of enforced overexpression of Hemgn in primary hematopoietic cells.
5-FU was used to generate a hematopoietic progenitor cell-enriched population
for vector transduction. Because the transduction efficiency of MSCV-HemgnIRES-GFP vector was 13%, we diluted the GFP control and HOXB4overexpressing bone marrow cells with mock cells to the same proportion to
examine whether there will be a growth advantage in subsequent liquid culture
and CFU-C experiments (Figure 4-3).
We found that cells transduced with MSCV-Hemgn-IRES-GFP vector had a
significant growth advantage over non-transduced cells in liquid culture, similar to
the results seen with the HOXB4 vector (Figure 4-4). This was demonstrated by
the increased GFP percentage of Hemgn-overexpressing and HOXB4overexpressing cells at day 6 (Hemgn: 31%; HOXB4: 44%), day 11 (Hemgn:
50%; HOXB4: 78%) and day 16 (Hemgn: 77%; HOXB4: 91%) from 3 biological
independent experiments (Figure 4-4). In contrast, cells transduced with GFP
control vector did not show any growth advantage during this time. These results
show that, Hemgn and HOXB4 promote expansion of hematopoietic cells in
liquid culture.
4.4.3 Hemgn Promoted Myeloid Progenitor Cell Expansion In Vitro
As HOXB4 overexpression can also cause dramatic expansion of myeloid
progenitor cells,95 we examined whether Hemgn has similar effect in CFU-C
assays. The 13% cell mixtures were plated in semi solid medium and re-plated 7
days later to generate secondary CFU-C colonies. This assay allowed
quantitation of myeloid progenitor expansion. We found that Hemgnoverexpressing bone marrow cells generated significiantly more secondary CFUC colonies than mock (4.9 fold) and the GFP control cells (6.1 fold) (Figure 4-5).
As a positive control, the HOXB4-overexpressing bone marrow cells generated
7.9 fold and 9.9 fold more secondary colonies than mock and GFP control cells,
respectively. To confirm that the detected increase of secondary CFU-C colonies
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Figure 4-3. Experimental design of in vitro expansion assays.
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Figure 4-4. Growth advantage of Hemgn-overexpressing bone marrow cells
in liquid culture. Flow cytometry-detected GFP percentage of the transduced
bone marrow cells at 6th, 11th, 16th day in liquid culture post-transduction. 0th day:
the day virus transduction was finished, when GFP percentage of each sample
was normalized to 13% with mock cells. Three biological independent
experiments were applied for statistics.
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Figure 4-5. Growth advantage of Hemgn-overexpressing hematopoietic
progenitor cells in methylcellulose culture. Secondary CFU-C colony number
generated from the 13% GFP positive cell mixture. Three biological independent
experiments were applied for statistics.
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were indeed caused by expansion of the initial sub-population of Hemgn or
HOXB4-transduced bone marrow cells, the proportion of GFP positive cells were
scored by flow cytometry both from primary and secondary CFU-C dishes (Figure
4-6). We found that in Hemgn-overexpressing cells, the GFP percentage
increased from the pre-plating 13% to 32% in cells collected from primary
colonies and to 69% in cells collected from secondary colonies, respectively
(Figure 4-6). As a positive control, GFP percentage in HOXB4-overexpressing
cells increased from the pre-plating 13% to 58% in primary colony cells and to
91% in secondary colony cells, respectively. GFP control bone marrow cells did
not show any expansion advantage. This result reveals that, Hemgn and HOXB4
transduced cells had a selective advantage during growth both in primary and in
secondary semi-solid CFU-C assays.
4.4.4 Hemgn Protected Bone Marrow Cells from Apoptosis
To explore the potential cellular mechanism of how Hemgn promotes
expansion of bone marrow cells in vitro, we first examined apoptosis phenotypes
in Hemgn-overexpressing bone marrow cells. Transduced bone marrow cells
were cultured for 6 days in cytokine-supplemented DMEM medium containing 20
ng/ml IL-3, 50 ng/ml IL-6 and 50 ng/ml SCF. The majority of those cells were
viable (89%), and only a very small population was Annexin V+/ Propidium
Iodide(PI)- (7%). The principle of this assay is based on the fact that the
phosphotidylserine components of the phospholipid bilayers are externalized
during the apoptotic process and can be detected by fluorescence labeled
Annexin V, which is a member of the annexin family of calcium-dependent
phospholipid-binding proteins. Under these conditions in liquid culture, Hemgn
and HOXB4 decreased the proportion of Annexin V+/PI- cells from 7% to 2% and
1% respectively (data not shown). In order to induce more cells to undergo
apoptosis, we then transferred these cells into DMEM medium containing 1%
FBS and no cytokines. Sixteen hours later, cells were stained for Annexin V and
PI. Flow cytometry was used to gate on the GFP positive and negative fractions
for apoptosis detection.
A representative experiment (Figure 4-7) shows that both Hemgn and HOXB4
transduction resulted in a much smaller fraction of Annexin V+/PI- cells than seen
in non-transduced cells or GFP control-transduced cells. Statistic analysis from 3
biologically-independent experiments (Figure 4-8) demonstrated that GFP
control-transduced cells had a similar percentage of Annexin V+/PI- cells (45%)
as non-transduced cells (43%) as expected. In contrast, HOXB4 transduction
protected cells from apoptosis, demonstrated by the decrease of the percentage
of Annexin V+/PI- cells in the transduced GFP positive population (3%). Hemgn
transduction also resulted in an anti-apoptosis effect as seen by gating on
transduced cells (17% Annexin V+/PI-). This was significantly different than that
seen with non-transduced GFP negative cells (53% Annexin V+/PI-) (Figure 4-8).
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Figure 4-6. Flow cytometry-detected GFP percentage of bone marrow cells
collected from primary and secondary CFU-C colonies. Three biological
independent experiments were applied for statistics.

80

Figure 4-7. Flow cytometry analysis for apoptosis in GFP positive vs.
negative population of transduced bone marrow cells in cytokine-depleted
and serum-reduced medium.
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Figure 4-8. Quantification and statistics of three independent experiments
for apoptosis in GFP positive vs. negative transduced bone marrow cells in
cytokine-depleted and serum-reduced medium.
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4.4.5 Hemgn Overexpression Has No Direct Effects on Cell Cycle in
Hematopoietic Cells
We have already shown that Hemgn can protect transduced cells from
apoptosis, which could be one potential cellular mechanism of the way Hemgn
promotes expansion of bone marrow cells in vitro. To explore another potential
cellular mechanism, that is, whether Hemgn increases cell proliferation by
altering cell division rates, cell cycle analyses were performed. For this assay,
the transduced cells were cultured for 6 days in cytokine-supplemented medium
and then were sorted to separate GFP positive and negative populations, which
were then stained with PI for DNA content analysis. The percentage of cells at
the G1, S, and G2-M phases of the cell cycle was determined (Figure 4-9). We
found that the percentage of cells in S phase was similar in Hemgn-transduced
cells versus cells transduced with the control vector (38% and 42% respectively),
indicating that the cell proliferation rate was not altered in Hemgn-overexpressed
cells. The percentage of cells in G1 and G2-M phases were also not changed in
Hemgn samples.The percentage of cells in S phase in the HOXB4overexpressing sample was slightly higher than the control (49% and 42%
respectively) (Figure 4-9), suggesting that HOXB4 could promote some cells to
undergo division.
4.5 Discussion
Our results in overexpression studies show that Hemgn recapitulates the
phenotype of HOXB4 in promoting expansion of bone marrow cells and myeloid
progenitor cells in vitro. These results indicate that increased Hemgn expression
may play a direct role in the mechanism by which HOXB4 induces myeloid
progenitor expansion. Our results also suggest that Hemgn may play a role in
hematopoietic stem cell self-renewal; however, transplant experiments will be
required to prove this hypothesis.
Self-renewal that results in expansion of hematopoietic stem and progenitor
cells requires the combination of both survival and proliferation signals together
with the inhibition of apoptosis and differentiation. A large body of evidence
suggests that suppression of apoptosis is required for hematopoietic stem cell
survival and thus self-renewal.21;22;187;188 EDAG has been reported to enhance
survival of Ba/F3 cells by protecting them from apoptosis following IL-3
withdrawal.172 HOXB4 has also been shown to protect bone marrow cells from
the apoptosis-inducing effects of the TNF-a pathway.144 In this work, we have
found that both Hemgn and HOXB4 can protect bone marrow cells from
apoptosis in liquid culture, particularly following cytokine withdrawal, suggesting
an anti-apoptotic role of Hemgn and HOXB4 that may be important for selfrenewal of myeloid progenitors and/or hematopoietic stem cells.
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Figure 4-9. DNA content of vector-transduced bone marrow cells cultured
for 6 days post transduction. DNA content was represented as the percentage
of cells in G1, S or G2 and M phases. Left panel: non-transduced population;
Right panel: transduced population; Black: G1 phase; Grid: S phase; Grey: G2
and M phase.
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The cell cycle was not altered in Hemgn overexpressed cells, but was altered
in HOXB4 overexpressed cells 6 days after transduction. These results suggest
that the enhanced cell proliferation in HOXB4 samples was probably due to
downstream events independent of Hemgn induction. We did observe an
increased cell number in Hemgn and HOXB4 bone marrow samples compared to
mock and vector control samples in the liquid culture assays. This is consistent
with the result that the proportion of cells in S phase in Hemgn and HOXB4
samples was higher than GFP or mock control samples 16 days after
transduction. As day 16 is a very late stage in the liquid culture, the observed
consequence could be due to multiple causes. For example, Hemgn could block
differentiation of cells in culture, resulting in enhanced cell number, a possibility
suggested by the observation that EDAG overexpression can block the
differentiation of HL-60 cells.172 There is also some evidence that ectopic HOXB4
expression can cause a delay in myeloid differentiation.154;189
These in vitro results suggest further investigations to study whether Hemgn
can cause expansion of hematopoietic stem cells in in vivo transplantation
assays. We did transplant lethally irradiated recipient mice with donor-derived
bone marrow cells transduced with Hemgn vector containing the GFP reporter
gene. The reconstitution of GFP positive cells was poor in recipient mice 6 weeks
post transplantation. The low titer and modest expression of the retroviral
MSCV-Hemgn-IRES-GFP vector limited the ability to perform transplant assays.
Further work is required to generate new lentiviral vectors for high and stable
protein expression of Hemgn for use in transplant assays and to solve these
technical issues.
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CHAPTER 5. DISCUSSION
5.1 General Summary and Discussion
5.1.1 Target Genes Downstream of HOXB4
By using the inducible HOXB4-ERT2 system, screening by expression
microarray analysis identified a relatively small subset of potential downstream
target genes (n=77) of HOXB4. The high correlation of gene expression patterns
obtained with the GFP control samples and the HOXB4-ERT2 samples
demonstrates no global change of gene expression following HOXB4 activation,
thereby indicating that only a few key mediators exist downstream of HOXB4 and
function in hematopoietic cell expansion. In eukaryotes, activation of gene
expression involves an ordered assembly of transcriptional regulators, chromatinmodifying factors, RNA polymerase II, and associated general transcription
factors onto cis-regulatory elements embedded in chromatin. Chromatinremodeling factors play an integral role in gene activation by perturbing
chromatin structure and making specific loci permissive for transcription. Change
of chromatin-remodeling factors usually causes the following global gene
expression change. For example, knockdown of Bmi-1 and Mel-18, which belong
to Polycomb group of transcriptional regulators, causes global changes in gene
expression.190;191 Our data indicates that epigenetic alterations and chromatin
reorganization are not induced by HOXB4, at least at a global level. Thus,
chromatin-remodeling factors are probably not direct targets of HOXB4. This
inference is consistent with a recent study when HOXB4 was overexpressed.144
Of the 77 candidate target genes, 44 were upregulated and 33 were
downregulated by HOXB4. This suggests that either gene activation or
repression can be mediated by HOXB4, which is consistent with previous reports
showing that HOX family members can activate or repress gene expression.141
The choice between activation and repression of target genes by HOXB4 is not
well-understood and is probably context specific. To distinguish the transactivation activity of HOXB4 from its repressive function, an engrailed repression
domain-fused HOXB4 was introduced into hematopoietic stem and progenitor
cells and was shown to completely block their expansion.95 In contrast, a VP16
activation domain-HOXB4 fusion protein was fully active in conferring expansion,
suggesting the requirement of trans-activation function, but the dispensability of
repressive function, of HOXB4 in hematopoietic stem and progenitor cell
expansion. Therefore, the genes that were downregulated by HOXB4 in our
microarray analysis may be less functionally relevant to the biological activity of
HOXB4 in stem cell expansion. On the other hand, it is still possible that some of
the repressive events are important. For example, Ms4a4c (membrane-spanning
4-domains, subfamily A, member 4C), a trans-membrane protein that is
expressed in hematopoietic stem and progenitor cells with unknown function,
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was downregulated following HOXB4 activation. When it was overexpressed in
bone marrow cells through retroviral vector-mediated gene transfer, Ms4a4c
robustly suppressed secondary CFU-C colony formation compared to the mock
and the empty vector controls (Jie Jiang, unpublished data). These data indicate
that downregulation of Ms4a4c could be involved in HOXB4-mediated expansion
of hematopoietic progenitor cells. To test this hypothesis, one could knockdown
Ms4a4c expression in the hematopoietic stem and progenitor cell through shRNA
to investigate its effect on hematopoietic stem and progenitor cell expansion.
5.1.2 The Mechanism of Hemgn as a Functional Direct Target of HOXB4
We show that when overexpressed, Hemgn can partially recapitulate the
phenotype of HOXB4 in promoting the expansion of bone marrow cells and
myeloid progenitor cells in in vitro assays. These results suggest that Hemgn can
potentially play a mechanistic role in HOXB4-induced myeloid progenitor
expansion. The mechanism of Hemgn as a functional target of HOXB4 is most
likely due to the fact that Hemgn can protect cells from apoptosis. This antiapoptotic effect was most apparent when the three cytokines: SCF, IL-3 and IL-6
were withdrawn and serum was reduced from culture medium, which is a
common assay for inducing apoptosis in hematopoietic cells. However, we did
note that the Hemgn overexpression phenotype only partially recapitulated the
HOXB4 overexpression phenotype. Here I propose several explanations for this
discrepancy.
First, retroviral vector-mediated expression of Hemgn usually results in high
level expression in bone marrow cells due to strong retroviral promoter. In
contrast, the mRNA level of Hemgn was increased merely 2 to 5 fold by HOXB4
overexpression. It is possible that different levels of transgene expression can
result in quantitative or even qualitative differences in phenotype. For instance,
the enforced expression of Hemgn may cause cytotoxicity which diminishes
myeloid expansion and therefore results in a net effect that only partially
resembles HOXB4. I hypothesize that a threshold of Hemgn expression level
exists for optimal expansion of hematopoietic progenitor cells, like the case of
HOXB4 itself.153 When Hemgn is expressed at a high level, the toxic effects of
Hemgn may inhibit further expansion of hematopoietic progenitor cells. To test
this hypothesis, overexpressing Hemgn in different doses using retroviral vectors
or generation of a TAT-Hemgn fusion protein could be applied to detect such a
threshold.
The second explanation of the functional difference between HOXB4 and
Hemgn is that other target genes regulated by HOXB4 are likely to be corequired for the maximal effect of HOXB4. In support of this notion, we found that
although Hemgn can protect bone marrow cells from apoptosis like HOXB4, it
cannot promote S phase entry and proliferation compared to the cells transduced
by HOXB4. Thus, there probably are other target genes of HOXB4 that contribute
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to the expansion phenotype by promoting cell division rate. To test this
hypothesis, one could overexpress Hemgn together with other direct targets of
HOXB4 in bone marrow cells. In detail, one could transduce bone marrow cells
with both MSCV-Hemgn-IRES-GFP and MSCV-new target cDNA-IRES-RFP
retroviral vectors. The GFP and RFP double positive cells could then be sorted
as a source of cells transduced with both genes for futher functional studies to
test whether overexpression of both genes can fully recapitulate the phenotype of
HOXB4 overexpression, particularly on its effects in both anti-apoptosis and cell
cycle progression.
5.1.3 Relationship between Hemgn Expression and Endogenous Hoxb4
Our results showed that the endogenous Hemgn mRNA was increased about
2 to 5 fold following HOXB4 activation in expanded Lin- bone marrow cells.
Furthermore, the exogenous expression of Hemgn induces expansion of murine
bone marrow and myeloid progenitor cells in vitro. One important question
suggested by my results is “What is the normal function of Hemgn?”. The
expression of Hemgn is restricted to the testis and hematopoietic tissues.170;171
This pattern of expression is similar to Hoxb4 in hematopoietic tissues, with a
spatial and temporal pattern in hematopoietic sites during embryogenesis.
Hemgn is first expressed in blood islands of yolk sac, then in fetal liver, and
finally in the adult spleen and bone marrow.170 In adult bone marrow, Hemgn is
predominantly expressed in developmentally primitive stem and progenitor
populations, and its expression decreases during differentiation.170 These facts
are consistent with the hypothesis that endogenous Hemgn may play a role in
regulating normal hematopoiesis. To address this question, we are generating
mice in which both alleles of Hemgn are disrupted to test its role in development,
particularly hematopoiesis.
To understand whether the expression of Hemgn can be regulated by
endogenous Hoxb4, we performed quantitative real-time PCR assay in Hoxb4deficient bone marrow cells158 and detected a 5-fold decrease in Hemgn mRNA
level in c-kit+Scal-1+Lin- cells when compared to wild type cells. These results
suggest that Hemgn may also be regulated by endogenous Hoxb4 as opposed to
overexpression constructs. However, the detectable expression of Hemgn in the
absence of Hoxb4 indicates the presence of some degree of Hoxb4-independent
regulation of Hemgn expression. One possibility is that other HOX4 paralog
members could provide redundant function through upregulating Hemgn
expression.
It is important to emphasize that, in this study, we were interested in defining
the targets in the context of overexpressing an ectopic HOXB4 gene in mice,
given that this is the biological setting in which expansion of hematopoietic
progenitor cells have been noted. We recognize that these data may not
necessarily represent target genes of endogenous Hoxb4 that is expressed at
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significantly lower levels. To further explore the genes regulated by endogenous
Hoxb4, we could use microarray analysis to compare the gene expression
difference in c-kit+Scal-1+Lin- cells between wild type and Hoxb4-/- mice. The
disadvantage of this system is that the activity of Hoxb4 could not be temporally
induced and thus the candidate list may not represent immediate early response
genes. To overcome this disadvantage, one could replace the endogenous
Hoxb4 gene with Hoxb4-ERT2 fusion gene. Hoxb4-ERT2 is inactive unless the
mice are treated with tamoxifen, which can temporally induce Hoxb4-ERT2
activation. Microarray analysis can be applied to compare the gene expression
profile in c-kit+Scal-1+Lin- cells generated from tamoxifen treated Hoxb4-ERT2
mice and from non-treated Hoxb4-ERT2 mice to identify the early response genes
regulated by Hoxb4.
5.1.4 Upstream Regulation of Hemgn: Other Mechanisms
Although HOXB4 was proved to be recruited to its consensus binding motifs in
Hemgn promoter by ChIP assay in hematopoietic progenitor cells in our study, it
does not exclude the possibility of involvement of other regulatory elements of
Hemgn. HOXB4 could regulate Hemgn expression by recruiting other
hematopoietic regulators that bind directly or indirectly to the Hemgn promoter.
Alternatively, the recruitment of other transcription factors could be HOXB4independent but could be necessary for maximal HOXB4 activity. The Hemgn
promoter contains binding sites of multiple transcription factors in addition to
HOXB4, including GATA-1, AML-1, Evi-1 and ETS.184 HOXB4 may directly
interact with AML-1, Evi-1 or ETS proteins. To test this hypothesis, one could
perform co-immunoprecipitation assay using HOXB4 antibodies. If a positive
interaction partner can be found, one can map the interaction domain and test its
function in HOXB4-mediated hematopoietic cell expansion.
GATA-1, a member of the GATA family of transcription factors, is expressed in
primitive and definitive erythroid cells, megakaryocytes, eosinophils, and mast
cells. It is essential for normal erythroid and megakaryocytic development. GATA1 was shown to be recruited to the promoter of Hemgn in an AML cell line, and to
transactivate HEMGN in K562 cells.184 Gata1-/- mice die during early
embryogenesis due to severe anemia with erythroid differentiation block at the
proerythroblast stage and rapid apoptosis of those cells. Intriguingly, human
HEMGN protects K562 cells from apoptosis and prevents their differentiation.
Therefore, Hemgn may play a positive role in cell survival and a negative role in
erythroid terminal differentiation as a consequence of GATA-1 upregulation in
erythroid cells.
AML1 (Acute myeloid leukemia 1) is a transcription factor essential for
hematopoiesis. AML1 gene is the most common target of chromosomal
translocations in human leukemias. AML1-Evi-1 fusion protein can transform
hematopoietic stem cells.192 AML1 binds to sequences present in the regulatory
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regions of a number of hematopoiesis-specific genes, including certain cytokines
such as GM-CSF (granulocyte macrophage colony-stimulating factor).193 Evi-1
has been recognized as a dominant oncogene associated with murine and
human myeloid leukemia. It is a common and essential regulator for proliferation
of embryonic and adult hematopoietic stem cells and transformed leukemic
cells.194 Members of the ETS family have been implicated in a wide variety of
functions including the regulation of cellular differentiation, cell cycle control, cell
migration, cell proliferation, apoptosis and angiogenesis. Multiple ETS factors
have been found to be associated with cancer through gene fusion. These
transcription factors which show potential binding sites in the promoter of Hemgn
possibly provide other upstream signals in regulating Hemgn expression.
5.2 Short-Term Future Directions
Although overexpression of Hemgn partially recapitulated the effect of HOXB4
in mediating hematopoietic progenitor cell expansion in vitro, it is unknown
whether Hemgn upregulation by HOXB4 is required for the observed
hematopoietic stem and progenitor cell expansion. To complement our studies,
we will use short hairpin RNA (shRNA) to knockdown endogenous Hemgn in
cells overexpressing HOXB4 to determine if this will lead to reduced
hematopoietic stem and progenitor cell expansion. We have designed a set of
different shRNA sequences targeting different regions of Hemgn, including the
cDNA coding region and 3’ UTR. Those shRNA nucleotides were individually
cloned into a lentiviral vector containing the MSCV promoter. Lentiviral vector
supernatant will be collected from transiently transfected 293T cells and used to
transduce GPE+86 cells that constitutively overexpress exogenous Hemgn. The
knockdown efficiency of different shRNAs will be tested by western blotting using
an anti-Hemgn antibody. Preliminary experiments have identified at least two of
the short hairpin RNAs that efficiently knockdown the protein level of exogenous
Hemgn. We will transduce bone marrow cells with both the Hemgn-shRNA
lentiviral vector and the MSCV-HOXB4-IRES-YFP vector. The cells successfully
transduced by both vectors can be sorted for functional assays to evaluate the
effects of Hemgn deficiency on HOXB4-induced hematopoietic progenitor cell
expansion.
The disadvantages of any knockdown strategy are the potential off-target
effects of the short hairpins and the inability to fully suppress target protein
expression. To circumvent these drawbacks, generation of Hemgn-null mice by
targeted gene disruption would be the optimal strategy and is ongoing. To study
the physiological role of Hemgn in hematopoietic tissues, and to avoid the
potential failure of germline transmission due to the lack of Hemgn, we have
generated a conditional allele of Hemgn flanked by loxP sites, which can be
removed through a hematopoietic tissue specific Cre (MMTV-Cre) during
development or an inducible Cre (Mx1-Cre) in adult mice. The effects of Hemgn
deficiency on hematopoiesis, particularly on hematopoietic stem and progenitor
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cells expansion, will be carefully investigated. We will perform liquid culture and
CFU-C assays in vitro and competitive bone marrow transplantation in vivo. If the
endogenous Hemgn is critical to hematopoietic stem cell function, I might expect
to see a defect in self-renewal of Hemgn-deficient hematopoietic stem and
progenitor cells. To further explore whether Hemgn is a key target of HOXB4, we
can overexpress HOXB4 in Hemgn-deficient cells and assess its biological
consequence similarly as I mentioned before.
5.3 Long-Term Future Directions
5.3.1 Biochemical and Functional Characterization of Hemgn
Hemgn is a newly identified protein and its biochemical and functional
characterization is far from well-understood. A nuclear-localization signal
together with a coiled-coil domain, but no other recognizable motifs, is present in
the sequence of Hemgn.170 Careful characterization of this protein at biochemical
level will be important for future studies. The lack of a DNA-binding domain
reasonably lowers the possibility that Hemgn is a transcription factor. We will
fuse Hemgn with a known DNA-binding motif and test its ability to activate or
repress reporter gene expression. If we see no activity of this fusion protein in
regulating gene expression, it would suggest that Hemgn has no transactivation
domain by itself. Otherwise, if we see some activity of this fusion protein in
regulating reporter gene expression, it would suggest that Hemgn may function
as a cofactor that can recruit other transcriptional regulators through direct
interaction. If the second situation occurs, it will be interesting to identify the
interaction partners of Hemgn. Since coiled-coil proteins usually interact with
other coiled-coil proteins for protein-protein recognitions and interactions, the
present coiled-coil domain in Hemgn should play an essential role in interacting
with other proteins for conveying the function of Hemgn. We can first make a
deletion mutation in the coiled-coil domain of Hemgn. I expect to see a loss of
Hemgn function in promoting hematopoietic progenitor cell expansion and in
protecting cells from apoptosis when its coiled-coil domain is deleted. If this is the
case, I will immuoprecipitate Hemgn in cells overexpressing wild type Hemgn or
mutant Hemgn with an anti-Hemgn antibody and then perform proteomics
analysis in order to identify its interaction partners. Since human HEMGN was
shown to regulate the expression of some key genes in hematopoietic stem cell
function,173 mouse Hemgn probably also acts as a transcription regulator through
interaction with other transcription factors. Thus, microarray analysis can be
conducted using wild type Hemgn and mutant Hemgn-overexpressing cells to
identify differentially expressed genes. For example, I expect to see expression
changes of genes that are involved in apoptotic pathways due to the fact that
Hemgn shows profound effect in protecting bone marrow cells from apoptosis.

91

5.3.2 Potential Clinical Use of Hemgn
Successful ex vivo hematopoietic stem cell expansion has been a long-sought
goal in hematopoietic stem cell transplantation and hematopoietic stem cell gene
therapy. Hemgn could potentially be used to achieve this goal. Since constitutive
expression of Hemgn by retroviral vectors may have unforeseen side effects,
such as insertional mutagenesis, transient exposure of hematopoietic stem cells
to Hemgn may offer a better approach. Recently, progress has been made to
directly deliver proteins into cells by fusing the protein with plasma membrane
penetrating peptide sequences. Several proteins and peptides are able to pass
through plasma membranes independent of classical receptor- or endocytosismediated process. An example is human immunodeficiency virus (HIV)-1
transactivator of transcription (TAT) protein. The small protein transduction
domain of TAT was fused to HOXB4 and was used to deliver TAT-HOXB4
protein into bone marrow cells.195 The TAT-HOXB4 protein is fully active in
supporting hematopoietic stem and progenitor cells expansion when added into
the culture medium.195 This process of TAT-based transportation is dependent on
heparan sulfate proteoglycan on the cell surface. The advantage of using this
strategy is to avoid conventional gene transfer approaches, which could be
tumorigenic due to gene integration into the genome. Furthermore, the TATbased protein transportation process is rapid, efficient and the dose is easy to
control. Since Hemgn could have dose-dependent effects or side effects due to
continuous constitutive expression as I discussed above, using a TAT-Hemgn
fusion protein would be a promising approach to determine the optimal dose of
TAT-Hemgn to mediate hematopoietic cell expansion in vitro. However, the
biological activity of TAT-Hemgn should be determined first because TAT-Hemgn
could potentially be inactivated when penetrating the plasma membrane, a
phenomena that has been seen in some TAT-fusion proteins.
5.3.3 Identification of Other Direct Target Genes of HOXB4
The partial recapitulation of HOXB4 mediated hematopoietic stem and
progenitor cell expansion by overexpression of Hemgn may suggest either that
some other targets we identified using our gene expression profile approach, or
some yet to be identified new targets are necessary for fully executing the
HOXB4 downstream activity. In addition to studying other candidate genes in the
generated 77 target list using the similar methods as we used before, other
strategies such as ChIP-seq (Chromatin immunoprecipitation followed by
sequencing) assay could be used to complement our microarray data. By using
ChIP-seq, we can obtain genome-wide profiling of HOXB4 binding sequences.
ChIP–seq offers higher resolution, less noise and greater coverage than its
array-based predecessor ChIP–chip, which necessarily introduces some bias, as
an array is restricted to a fixed number of probes.196 Another important
advantage of ChIP-seq over the expression array is that only a small amount of
DNA (10-50 ng) is required for generating reliable signal,196 which would allow us
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to use a purified pool of hematopoietic stem cells, instead of a mixed population
of hematopoietic progenitor cells to obtain enough DNA sample.
5.4 Detailed Consideration of These Results and Their Impact on
Understanding the Molecular Mechanisms of Hematopoietic Stem Cell
Expansion
5.4.1 Hematopoietic Stem Cell Self-Renewal and the Role of HOXB4
Self-renewal or expansion of hematopoietic stem and progenitor cells requires
the coordinated proliferation signals together with inhibition of apoptosis and
differentiation programs.
5.4.1.1 Survival Signals
Inhibition of apoptosis is essential for hematopoietic stem and progenitor cell
survival.197;198 Quiescent hematopoietic stem cells are resistant to cell cycle
checkpoint-induced apoptosis. In stress conditions, such as during in vitro
expansion cultures, apoptosis plays a major role in hematopoietic stem and
progenitor cell loss. Intrinsic apoptotic and extrinsic apoptotic pathways may both
be important for hematopoietic stem cell function.
The intrinsic apoptotic pathway is initiated from an intracellular signal, such as
DNA damage, defective cell cycle, loss of cell survival factors, or other types of
intracellular stress. This pathway involves the activation of pro-apoptotic Bcl-2
family members, Bax or Bak in the outer mitochondrial membrane, which
eventually causes cytochrome c release from the inter-mitochondrial membrane
space into cytosol. Cytochrome c in turn binds to the adaptor apoptotic protease
activating factor-1, forming the apoptosome, which is able to activate the initiator
caspase-9. Capase-9 can activate the downstream effector capases -3, -6 or -7
to cleave a variety of cellular substrates for executing apoptotic response. The
anti-apoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL and Mcl-1, act to prevent the
mitochondrial outer membrane permeabilization (MOMP) through inhibiting the
action of the pro-apoptotic Bcl-2 family proteins. The anti-apoptotic Bcl2 family
members are involved in maintaining the function of hematopoietic stem cells.
Mice lacking the anti-apoptotic Bcl-2 gene show massive cell death of lymphoid
cells.199 The absence of Bcl-xL causes embryonic lethality; and homozygous null
mutant mice die at E13.0 with massive cell death in neurons and immature
hematopoietic cells.200 Bcl-xL is also indispensable for the late maturation of
primitive and definitive erythroid progenitors.200 Inducible deletion of Mcl-1 gene
in mice results in the loss of early bone marrow progenitor populations including
hematopoietic stem cells.70 Overexpression of Bcl-2 in HSCs in vivo in a
transgenic mouse model results in apoptotic protection, and a moderate two fold
expansion of HSCs.22;201 Those hematopoietic stem cells overexpressing Bcl-2
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can outcompete wild type cells following reconstitution.22 Based on this
information, the intrinsic apoptotic pathway is important in hematopoietic stem
and progenitor cell expansion.
On the other hand, the extrinsic apoptotic pathway also shows its role in
hematopoietic cell expansion. The extrinsic apoptotic pathway starts with an
extracellular signal, such as Fas ligand and TNF-α, which activates specific
death receptors on the cell surface. In this case, the ligand binding induces
receptor clustering and recruitment of the adaptor protein Fas-associated death
domain (FADD) and the initiator caspases-8 or -10, forming a death-inducing
signaling complex (DISC). The initiator caspases then can be processed into
their active form and be released into the cytoplasm, where they activate effector
caspases -3, -6, or -7. For example, TNF-α is able to inhibit SCF-induced
expansion of hematopoietic progenitor cells in vitro.202
Our data proves that one mechanism of HOXB4 in promoting hematopoietic
stem and progenitor cell self-renewal is through protecting cells from apoptosis
by activating its direct downstream target gene-Hemgn. Human HEMGN was
shown to act as a transcriptional regulator to upregulate the expression of Bcl-2
and Bcl-xL.173 Due to their high homology, mouse Hemgn probably has the same
ability to regulate the anti-apoptotic Bcl-2 family members to perturb the intrinsic
apoptotic pathway. On the other hand, human HEMGN can activate NF-κB,
which in turn inhibits TNF-α receptor signaling induced apoptosis.172 It is possible
that mouse Hemgn can activate NF-κB to inhibit apoptosis. Intriguingly, HOXB4
was shown to inhibit TNF-α pathway and thereby to protect cells from TNF-α
induced apoptosis.144 Based on this information, the mechanism of Hemgn in
protecting HOXB4-overexpressing cells from apoptosis could be that Hemgn can
either inhibit intrinsic apoptotic pathways by upregulating of anti-apoptotic Bcl-2
family members, or inhibit extrinsic apoptotic pathways by interfering with TNF-α
receptor signaling. To test these possibilities, examination of both intrinsic and
extrinsic apoptotic pathways would be necessary in Hemgn-overexpressed cells.
For instance, the expression level of Bcl-2, Bcl-xL and Mcl-1 in Hemgnoverexpressing or -deficient cells could be examined, and inhibition of the NF-κB
pathway could be used to discern whether the effects of Hemgn can be
overcome.
5.4.1.2 Proliferation Signals
Apoptosis may not be the only mechanism of how HOXB4 functions in
promoting hematopoietic stem and progenitor cell self-renewal. Indeed, the fact
that HOXB4 can promote 40 fold expansion of hematopoietic stem cells in vitro is
not likely to be explained merely by its anti-apoptotic effect. For instance, Bcl-2
overexpression adequately provides a signal for hematopoietic stem cell survival
but merely causes a two fold expansion of hematopoietic stem cells because of
the inability to maintain those cells in the undifferentiated status.21 Other signals,
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presumably those regulating proliferation and differentiation, may also contribute
to the dramatic effect mediated by HOXB4.
Cyclins and cyclin-dependent kinases (CDKs) are critical components
controlling the cell cycle progression. When activated by a particular cyclin, CDK
can activate or inactivate target proteins to orchestrate entry into the next phase
of the cell cycle. Upon receiving mitotic signal, G1 cyclin-CDK complexes become
active to prepare the cell for S phase entry, through promoting the expression of
transcription factors that in turn induce the expression of S cyclins and enzymes
required for DNA replication, or through inducing the degradation of factors which
function as S phase inhibitors. For example, cyclin A-CDK2 complex plays a key
role in S phase entry through the phosphorylation of proteins including cdh1, Rb,
p21 and p27. Accelerated S phase entry caused by HOXB4 may significantly
contribute to the induced dramatic expansion of hematopoietic stem cells. The
lack of alteration in cell cycle distribution in Hemgn-overexpressing bone marrow
cells implies the existence of Hemgn-independent proliferative effects of HOXB4.
Although it is unknown which other target genes of HOXB4 regulate proliferation,
I hypothesize that cell cycle-related genes will be candidates. p21 contributes to
the quiescent state maintenance of hematopoietic stem cells.68 It has been
demonstrated that hematopoietic stem cell pool size is regulated by p21,
whereas proliferation of hematopoietic progenitor cells is regulated by p27.203;204
Deletion of p18 results in enhanced self-renewal of the primitive hematopoietic
cells and improved long-term engraftment.205 It is possible that HOXB4 can
downregulate the expression of those CDK inhibitors to facilitate more rapid S
phase entry. Correlatively, when HOXB4 was overexpressed in hematopoietic
cells from p21-/- mice, the primary CFU-C colony number and the repopulating
ability were significantly increased compared to that seen in the wild type bone
marrow cells.167 These findings suggest that HOXB4 may affect the cell cycle
process to promote hematopoietic stem cell self-renewal. However, the fact that
we did not detect any differential expression change of cell cycle regulators
including cyclins, CDKs and CDK inhibitors in our microarray data suggests that
HOXB4 may indirectly regulate the activity of these cell cycle regulators.
5.4.1.3 Anti-Differentiation Signals
Differentiation is the transition process of a less specialized cell into a more
specialized cell type. One cycling hematopoietic stem cell may generate two
daughter cells with identical biological properties as itself in the process of selfrenewal, or it may also divide to produce more differentiated progenies. During
the differentiation, hematopoietic stem cell gradually loses its totipotency, but the
generated hematopoietic progenitor cells may still retain a high degree of
multipotency.
HOXB4-overexpressed bone marrow cells showed a more homogenous
morphology and contained increased number of hematopoietic progenitor cells
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capable of generating primitive colonies in vitro.150 In contrast, control-transduced
bone marrow cells in long-term cultures showed hallmarks of myeloid
differentiation and reduced secondary colony forming activity.150 It is reasonable
to raise the possibility that HOXB4 has anti-differentiation function. Indeed,
evidence shows that ectopic expression of HOXB4 can cause delay or
impairment of myeloid differentiation.154;189 Similarly, there is also some evidence
that Hemgn can interfere with differentiation. Human HEMGN blocks the
differentiation of hematopoietic cell lines.172 Transgenic expression of human
HEMGN under the cd11a promoter in mice causes massive myelopoiesis and
repressed lymphlopoiesis.173 However, in contrast to these reports, we found
that either HOXB4 overexpression or Hemgn overexpression in bone marrow
cells did not cause blockage of myeloid differentiation based on the observation
of the secondary CFU-C assays in vitro. Furthermore, after the HOXB4 or
Hemgn-transduced donor bone marrow cells were transplanted into lethally
irradiated recipient mice, peripheral blood from the reconstituted recipient mice
were examined to confirm that no hematopoietic lineage was blocked due to the
overexpression of HOXB4 or Hemgn. These evidences indicate that HOXB4 or
Hemgn may not irreversibly block differentiation of hematopoietic stem and
progenitor cells, and thus suggest that HOXB4 or Hemgn could be good
candidates for therapeutic application since they are not potentially tumorigenic.
5.4.2 Cytokines, HOXB4 and Hemgn
It is known that in hematopoietic tissues, Hoxb4 expression can be
upregulated by cytokine-stimulation. TPO, Flt-3 or SCF were reported to induce
Hoxb4 expression up to 10 fold through activating its direct trimeric
transcriptional activator complex USF1(upstream stimulating factor 1)/USF2/NFY(nuclear factor Y).206-208 Cytokine receptor signals, such as TPOR, Flt3R and cKIT, are normally required for hematopoietic stem cell survival during in vitro
expansion. Now we provide potentially new insights into the downstream
pathways of these cytokines and HOXB4 through identification of a key
regulator-Hemgn. It is possible that Hemgn can be directly induced by Hoxb4
following cytokine stimulation and thus provide a signal for hematopoietic stem
and progenitor cell survival. Human HEMGN was shown to act as a
transcriptional regulator to upregulate the expression of Bcl-2 and Bcl-xL.173 Due
to high homology, mouse Hemgn probably has the same ability to regulate the
anti-apoptotic Bcl-2 family members to perturb the intrinsic apoptotic pathway.
The fact that hematopoietic stem cells from Bcl-2 transgenic mice are hyperresponsive to normal level cytokines than wild type cells21 is correlated to the
hypothesis that cytokine signaling may upregulate Hemgn which may further
upregulate Bcl-2. Consistently, we have shown that Hemgn was able to protect
bone marrow cells from cytokine withdrawal-induced apoptosis. This suggests
that Hemgn might substitute for the function of those cytokines to support cell
survival. To test this possibility, we can compare cultures with or without
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hematopoietic cytokines IL-3, IL-6 and SCF to see whether Hemgn can be
induced by these cytokines.
5.4.3 HOXB4 Functional Redundancy
Hoxb4 and its other three paralogs: Hoxa4, Hoxc4 and Hoxd4 were reported to
have similar effect in promoting hematopoietic stem and progenitor cell
expansion in vitro.167 Each paralog group 4 member was shown to both promote
proliferation and inhibit differentiation, enabling the exponential expansion of
hematopoietic progenitors from the c-kit+CD41+ hematopoietic progenitor cell
population of day 6 murine embryoid bodies.120 Similar findings about the
functions of HOX4 paralogs in promoting hematopoietic stem and progenitor cell
expansion in vivo were also obtained in our lab (Brian P Sorrentino’s lab,
unpublished data). This redundancy may explain the mild phenotype in Hoxb4-/mice.158 Quantitative analysis of mRNA from the fetal liver of Hoxb4-/- mice
revealed that a deficiency of Hoxb4 was associated with changes in the
expression levels of several other Hox genes.158 This result indicates that
alternative genetic pathways initiated by other Hox4 paralog members could
substitute for the function of Hoxb4. Since trans-paralog Hox genes share higher
degree of homology in sequence than cis-paralog Hox genes,104 it is suggested
that the same trans-paralog genes could functionally compensate for each other.
As Hox4 paralog genes lie on different chromosomes, it is feasible to examine
the degree of redundancy among them by breeding the mice with individual
disrupted gene. Although technically challenging, the analysis of double, triple
and even quadruple mutants of Hox4 paralogy genes could address the question
whether these Hox4 genes are functionally redundant in regulating
hematopoiesis.
Overexpression of HOXB4 in ES cell-derived primitive progenitors induced a
switch to the definitive hematopoietic stem cell phenotype and promoted rapid
hematopoietic stem cell expansion in vitro.146 Those HOXB4 induced progenitors
from ES cells engraft lethally irradiated adults and contribute to long-term,
multilineage hematopoiesis in primary and secondary recipients.146 During
embryogenesis, primitive hematopoiesis occurs in blood islands of the yolk sac at
approximately E7.5, and generates mainly primitive erythrocytes. The definitive
hematopoiesis occurs around E10.5 in aorta-gonadmesonephros
(AGM) regions, and then shifts to the fetal liver, and eventually to the spleen and
bone marrow in adult.209 The definitive hematopoiesis generates all
hematopoietic lineages, including hematopoietic stem cells with multipotent longterm repopulating activity. The mechanisms regulating the emergence of the
definitive hematopoietic stem cells at AGM region around E10.5 and the further
rapid expansion is poorly understood. Evidence shows that the autonomous
initiation and further expansion of definitive hematopoietic stem cells in the AGM
region can be enhanced by application of exogenous interleukin-3 (IL-3) which
acts as a proliferation and survival factor to the earliest hematopoietic stem cells
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in the embryo.210 The identified expression pattern of Hoxb4 and its other Hox4
paralogy members in definitive hematopoietic stem cells but not yolk sac
suggests the potential role of Hoxb4 and other Hox4 paralogy members in
promoting definitive hematopoiesis.105 Since Hoxb4 can be regulated by some
hematopoietic cytokines, it is possible that Hoxb4 acts downstream of IL-3 to
convey its function in enhancing the development of definitive hematopoietic
stem cells in embryo. Although the Hoxb4-dificient mice show essentially normal
hematopoiesis, deletion of the other three functionally redundant Hox4 paralogy
members could possibly lead to more severe phenotype in embryonic
hematopoietic stem cell development.
In gene expression profiling assays with c-kit+Lin- bone marrow cells that
constitutively overexpress HOXB4 or HOXC4 by retroviral vectors, we found that
many genes, including Hemgn, were commonly changed in HOXB4 and in
HOXC4 overexpressed samples compared to the control vector-transduced
samples (Brian P. Sorrentino’s lab, unpublished data). It is possible that HOX4
paralogs share at least some common downstream targets, such as Hemgn, for
enhancing expansion of hematopoietic stem and progenitor cells. Our real-time
PCR analysis in Hoxb4-/- c-kit+Scal-1+Lin- cells showed a 5-fold decrease in
Hemgn mRNA expression when compared to wild type cells. This result is not
contradictory to the finding that Hemgn is a direct target of HOXB4 for conveying
its function in promoting self-renewal, because the expression of Hemgn can still
be detected in the absence of Hoxb4 possibly due to redundancy of other group
4 paralogs. Investigation of whether Hemgn is a common direct target gene of
HOX4 paralog members is promising to unravel the mechanisms of HOX4
paralogs.
5.4.4 HOX Specificity
Functional specificity of Hox proteins depends on multiple mechanisms. Due to
the high degree of homology within the homeodomain, a core DNA sequence
“TAAT” is recognized and bound by the majority of Hox proteins.128 Structural
studies proved that DNA recognition by Hox proteins uses two sets of information
that provide different degrees of specificity. The first one uses DNA-contacting
residues that are common to all Hox proteins to promote Hox binding to AT-rich
sequences, such as “TAAT”. Some monomeric homeodomain-DNA structures
have been solved, and they show a very similar mode of DNA recognition.211 The
third recognition α-helix of homeodomain lies in the major groove of the DNA,
where it makes direct water-mediated contacts with specific bases and the
phosphate backbone. Ile47, Gln50, Asn51, and Met54 residues that are present
in all Hox homeodomains are primarily responsible for contributing to these
interactions.211 In addition, the N-terminal arm preceding the first α-helix typically
lies in the minor groove of the DNA. Arg5, an N-terminal arm residue present in
almost all homeodomains, is the most commonly observed residue in the minor
groove. The second set of determination factor for specificity in addition to
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common DNA-contacting residues is to use additional DNA-contacting residues
from the N-terminal arm and linker regions of Hox proteins.212 These additional
contacts are cofactor-dependent and paralog-specific. The N-terminal arm and
linker residues of Hox family members are conserved in a paralog-specific
manner. Thus, paralog-specific DNA sequences of Hox family members could be
recognized of by specific Hox-cofactor complexes. The same Hox paralogy
members probably share common targets for functional complement to initiate
the similar downstream biological events.
As discussed previously, the DNA binding specificity, affinity and
transregulating potential of a specific Hox protein can be modified by the flanking
DNA sequence or interaction with cofactors.129-131 A in vitro study showed that
specific Hox protein is able to bind to DNA consensus sequence with preferred
flanking sequence.129 In the future, by applying ChIP-chip and ChIP-seq
methodologies to each HOX protein, accurate DNA binding sequence of specific
HOX protein could be identified. Hox family members may bind to their specific
preferred DNA sequence as monomers or as heterodimers with other cofactors.
However, when high affinity Hox monomer binding sites were applied in vitro to
drive a reporter gene in Drosophila embryos, the generated expression patterns
were not consistent with their identified ability to bind homeodomain proteins.213 It
is plausible to hypothesize that currently unidentified factors can bind with Hox
proteins cooperatively or noncooperatively to these sites. As introduced in
Chapter 1, interaction with the TALE family cofactors to form dimeric or trimeric
Hox-Pbx/Meis complexes is hypothesized to increase the DNA binding ability of
some Hox family members to their target genes.136-138
DNA binding affinity of Hox family members can also be regulated by
posttranslational modification. For instance, phosphorylation of conserved
tyrosine residues in the homeodomain can decrease or increase the DNA binding
ability of Hox.133;134 In addition, the transcriptional specificity of Hox proteins also
lies in their ability to act both as transcriptional activators and repressors in
different contexts.
The fact that HOXB4 and other HOX4 paralog members but not other HOX
family member show similar function in promoting hematopoietic stem and
progenitor cell expansion indicates the specificity of HOX4 in regulating their
target genes in hematopoietic cells. To my understanding, although it is known
that PBX cofactor is not required for HOXB4-mediated expansion, it is possible
that other unidentified cofactors or collaborators of HOXB4 exist. To screen the
potential cofactor or collaborators of HOXB4, one could apply proteomics
methods following immunoprecipitation of HOXB4-containing complex. After that,
one could knockdown the identified interaction partner in HOXB4-overexpressed
cells to validate its function. Except the conserved “YPWM” cofactor-binding
domain, mutagenesis screen method could be applied in HOXB4 to identify other
unknown protein-interaction domains which contribute to its specificity. On the
other hand, phosphorylation could possibly increase the target binding affinity of
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HOXB4. HOXB4 was tyrosine phosphorylated in the transduced mouse and dog
cells, in which HOXB4 was introduced with high copy transcripts and thus high
protein expression level.214 Furthermore, the tyrosine phosphorylation of HOXB4
contributes to more profound expansion in the transduced cells.214 Whether
HOXB4 is phosphorylated in the transduced bone marrow cells can be
determined by mass spectrometry following immunoprecipitation of HOXB4. If
HOXB4 is phosphorylated, one could make point mutation (Ser/Thr/Tyr/ to Ala) in
phosphorylation sites and determine whether this modification abrogates the
ability of HOXB4 to activate target gene expression and thereby blunts its ability
to increase self-renewal.
5.4.5 HOXB4 and Leukemia
Hematopoietic stem cells may fail to fully regenerate the stem cell
compartment since their self-renewal ability is usually intrinsically limited and
subjected to exhaustion under the transplantation stress. This defect is possibly a
result of negative feedback mechanisms initiated when progenitors and mature
blood cells have been regenerated to their normal levels, which prematurely
inhibit further hematopoietic stem cell expansion.215;216 In contrast, HOXB4transduced hematopoietic stem cells are capable of fully reconstituting the stem
cell compartment but do not expand above levels normally observed in
unmanipulated mice.89 This indicates that HOXB4 overexpression does not
override the intrinsic regulatory mechanisms in vivo that maintain the HSC pool
size within normal limits. Several studies have indicated that, in steady-state
hematopoiesis, the cell cycle entry of hematopoietic stem cells is tightly
controlled. In mice, hematopoietic stem cell numbers remain relatively constant
throughout their adult life time. Hematopoietic stem cells may transit between
quiescent state in niche and undergoing cycling at non-niche sites in vivo.
Genetic studies show that increasing the number of osteoblastic cells can cause
parallel increases in the hematopoietic stem cell population, in contrast,
osteoblastic cell depletion can reduce BM cellularity.217;218 The finding that
HOXB4 overexpression did not lead to hematopoietic stem cell expansion
beyond the normal level is thus not surprising, since the limited size of
hematopoietic stem cell niche could prevent homing and residence of more
hematopoietic stem cells.
Despite a profound and consistent effect on expanding hematopoietic stem
and progenitor cells, overexpression of HOXB4 did not promote preferential
expansion along any hematopoietic lineage or lead to leukemia in mice after
persistent expression. In sharp contrast, retroviral overexpression of other HOX
family members such as HOXB3 or HOXA10 in a similar transplantation model
did lead to leukemia.118;219 The different outcomes suggest that these different
HOX proteins regulate different sets of target genes in hematopoietic cells. A
minimum of two events, one leading to enhanced proliferation with disabled
apoptosis and the other a block in differentiation, may be sufficient for leukemia
initiation.220;221 Of the known genetic events leading to leukemia, translocations
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leading to fusion transcription factors or activated signaling kinases are among
the most common events, and deletions in cell cycle checkpoint genes or
mutation in tumor suppressor genes could act as a secondary hit to initiate
leukemic transformation.222 One possible reason HOXB4 overexpression did not
cause leukemia in mice is that the intrinsic negative feedback regulatory
signaling pathways were activated to limit the accumulation of leukemic
transformation hits.
In contrast to the situation in mouse models as we discussed, myeloid
leukemia was reported in dogs two years after they were transplanted with
HOXB4-overexpressing CD34+ cells, but not in control retroviral vector
transplanted animals.157 shRNA-mediated knockdown of HOXB4 in the leukemic
cell line derived from one animal caused profound growth inhibition and cell
death, suggesting the involvement of HOXB4 in leukemogenesis.157 Those
HOXB4-overexpressing leukemic cells rapidly engrafted and expanded in
immune-suppressed recipient dogs to cause leukemia transmission.223 This,
although surprising, is not contradictory to the previous findings in mouse models,
where HOXB4 is not leukemogenic. Instead, in this case, HOXB4 overexpression
was demonstrated not to be the only contributor to the observed leukemic
phenotype in dogs.157;224 Retroviruses have long been known to cause leukemia
through insertional mutagenesis. In those two transplanted dogs, HOXB4containing retroviral vectors were shown to integrate into genomic locus of
several known proto-oncogenes, including c-myb and PRDM16, to elevate their
expression, thus favoring the engraftment and expansion of those clones.157;224
HOXB4 overexpression is thus probably not the single trigger to induce leukemia;
instead, it may function as an additional contributor for leukemogenesis following
retroviral vector integration-caused insertional mutagenesis. One reason that
HOXB4-overexpression leads to leukemia in dogs but not in mice possibly lies in
the fact that a relatively small number of transduced cells and relatively less
retroviral vector integration sites in transplanted mice lower the frequency of
insertional mutagenesis.157;224 On the other hand, perhaps a latency period
longer than the lifespan of a mouse is required for detection of leukemic
transformation.157;224 In summary, the observed myeloid leukemia is probably a
combined consequence of the deregulated proliferation caused by the activated
proto-oncogenes and the expansion advantage mediated by HOXB4 .157;224
Based on the information aforementioned, one could speculate that as a
potential application in gene therapy, retrovirus-mediated overexpression of
HOXB4 in large animals may pose a significant risk of leukemia. To circumvent
this drawback, new vectors based on lentivirus are in development, which may
decrease the frequency of insertional mutagenesis.158
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